Autoinjector apparatus

This application claims the benefits of US Provisional Patent Application No. 61/477553 filed on April 20, 2011 and incorporates it into the present application with reference to its entire disclosure.

The present application relates to an automatic injection device. More specifically, the present application relates to an automatic injection device having a reusable automatic syringe and a disposable cassette that can be used with the automatic syringe, in which the cassette hides the needle of the subcutaneous syringe before and after injection.

Prefilled subcutaneous syringes offer several advantages for the home market. These advantages include having a prefilled syringe for each drug having each drug in exactly a predetermined dose. Moreover, they are easily manipulated by simply advancing the stopper of the syringe. Apart from the cost of specific drugs used, prefilled syringes are also economically manufactured. Therefore, all these advantages make prefilled syringes commercially attractive.

Nevertheless, prefilled syringes also have significant drawbacks on the market. Specifically, many users feel frightened by the exposed needle or essentially unable to perform the injection. The unique purpose of hate exposed needles and to hide them from users due to related health and safety issues, and to automate injection operations to assist users in performing injections. We are developing various types of syringes and other devices.

In order to inject a fluid drug into a patient when using a subcutaneous syringe, three separate and separate tasks must generally be performed. These are 1) inserting the needle into the patient, 2) injecting the fluid drug from the syringe into the patient, and 3) pulling out the needle after completing the injection. For each operation, the strength and direction of the force applied to the syringe and the place where they are applied are different from other operations. For example, the task of inserting a needle is compared to the task of injecting a fluid drug. Inserting the needle requires applying only minimal force to the syringe and applying force over a very short period of time. On the other hand, injecting a drug requires more force. In addition, this force must be applied to the plunger of the syringe for a relatively long period of time. Compared to both of these tasks, pulling out the needle requires applying force in the opposite direction. These and other similar considerations become important when automating the injection process.

<p><patcit num="1"><text>U.S. Patent Application Publication No. 2009/0292246</text></patcit><patcit num="2"><text>U.S. Patent Application Publication No. 2010/0022955</text></patcit><patcit num="3"><text>International Publication No. 2009/143255</text></patcit></p>

<p>Springes for generating forces on syringes in automated processing have been used for a variety of purposes. However, the characteristic of the spring is that the strength and direction of the spring force cannot be changed. Therefore, the spring does not make them useful for multi-working operations. This limitation is particularly pronounced during syringe injection, which requires precise control of continuous forces of varying intensities (needle insertion and drug injection). This limitation can be particularly problematic when it is desirable to inject different agents with different fluid viscosities using the same material from time to time.</p><p>In addition to these mechanical considerations, the design of automatic syringes requires usability considerations. In particular, it is desirable that the needle of the syringe be operably hidden from the user's vision. Preferably, this hiding is maintained before, during and after the infusion process. Further, preferably, the operation of the syringe is limited only when the syringe is accurately positioned for infusion.</p><p>Therefore, an improved automatic injection device is required.</p>

<p>This specification relates to a disposable cassette for use with an automated syringe. The cassette is a housing and an inner sleeve that is located within the housing and is movable between first and second positions, wherein the inner sleeve can have a syringe placed therein. And a lock cap for fixing the syringe in the inner sleeve, the lock cap being attached to the tip of the inner sleeve and capable of contacting the tip of the syringe.</p><p>In one form of cassette, the lock cap comprises an elastic bumper capable of contacting the tip of the syringe.</p><p>In a cassette according to one form, the inner sleeve comprises at least one receiving portion at its tip and the lock cap comprises at least one arm member inserted into the receiving portion.</p><p>In one form of cassette, at least one arm member of the lock cap comprises a hook-like means for gripping the inner surface of the inner sleeve.</p><p>In one embodiment of the cassette, the cassette further comprises a barrel and an injection needle disposed within an inner sleeve.</p><p>In one embodiment of the cassette, the cassette further comprises a shield remover extending through an opening at the proximal end of the housing for removing the needle shield of the syringe.</p><p>In one form of cassette, the shield remover comprises a spring-loaded tab, which is located in an aperture defined on the wall of the housing.</p><p>In a cassette according to one embodiment, the shield remover comprises an elongated body having a proximal end and a distal end, the distal end comprising at least one flexible tongue, which is the shield remover. When the external device is removed from the cassette, it expands outward to prevent the shield remover from being reinserted into the cassette.</p><p>In a cassette according to one form, the cassette further comprises a syringe with a barrel and an injection needle.</p><p>In one form of cassette, the cassette further comprises a therapeutic agent in a syringe.</p><p>In one form of cassette, the therapeutic agents are Epogen®, Aranesp®, Enbrel® Neulasta®, Neupogen. ) (Registered Trademarks), Nplate®, Vectibix®, Sensipar®, Xgeva® and Prolia ( Selected from a group of registered trademarks).</p><p>In one form of cassette, the therapeutic agent is an antibody against IL-17 receptor A.</p><p>In one form of cassette, the therapeutic agent is an antagonist of angiopoietin-2 (eg, AMG36).</p><p>In one form of cassette, the therapeutic agent is a TNF blocker or inhibitor.</p><p>In one form of cassette, the TNF blocker or inhibitor is etanercept.</p><p>In one form of cassette, the TNF blocker or inhibitor is adalimumab, ertolizumab, golimumab or infliximab.</p><p>In one form of cassette, the cassette further comprises a cassette identification means on the surface of the housing, allowing an automated syringe to identify the cassette.</p><p>In one form of cassette, the cassette identification means comprises at least one protrusion.</p><p>The present application further relates to a device for injecting a therapeutic agent. The device comprises an automated syringe and a disposable cassette for use with the syringe, the cassette being located in the housing and inside the inner sleeve, which is located within the housing and is movable between the first and second positions. It comprises a syringe disposed in the sleeve and a lock cap for fixing the syringe in the inner sleeve, the lock cap being attached to the tip of the inner sleeve and in contact with the tip of the syringe.</p><p>In one embodiment, the lock cap comprises an elastic bumper that contacts the tip of the syringe.</p><p>In one embodiment, the inner sleeve comprises at least one receiving portion at its tip and the lock cap comprises at least one arm member inserted into the receiving portion.</p><p>In one embodiment, the at least one arm member of the lock cap comprises a hook-like means for gripping the inner surface of the receiving portion of the inner sleeve.</p><p>In one embodiment, the cassette further comprises a shield remover extending through an opening at the proximal end of the housing to remove the needle shield from the syringe.</p><p>In one embodiment of the device, the shield remover comprises a spring-loaded tab, the tab is located within an aperture defined on the wall of the housing, and the shield remover is removed from the cassette. To prevent that.</p><p>In one embodiment, the automated syringe, when the cassette is placed inside the syringe, pushes the tabs out of the aperture defined on the wall of the housing, thereby removing the shield remover from the cassette. Equipped with pins to enable.</p><p>In one embodiment of the device, the shield remover comprises an elongated body with a proximal end and a tip, which provides at least one flexibility that extends outward when the shield remover is removed from the cassette. It has a tongue to prevent the shield remover from being reinserted into the cassette.</p><p>In one embodiment of the device, the device further comprises a therapeutic agent in a syringe.</p><p>In one form of the device, the therapeutic agents are Epogen®, Aranesp®, Enbrel®, Neurasta®, Newpogen®, Nplate®, Bek. It is selected from the group consisting of Tibics (registered trademark), Sensiper (registered trademark), Zygeba (registered trademark) and Prolia (registered trademark).</p><p>In one form of the device, the therapeutic agent is an antibody against IL-17 receptor A.</p><p>In one form of the device, the therapeutic agent is an antagonist of angiopoietin-2 (eg, AMG36).</p><p>In one form of the device, the therapeutic agent is a TNF blocker or inhibitor.</p><p>In one embodiment of the device, the TNF blocker or inhibitor is etanercept.</p><p>In one embodiment, the TNF blocker or inhibitor is adalimumab, ertolizumab or infliximab.</p><p>In one embodiment, the cassette further comprises a cassette identification means on the surface of the housing, allowing an automated syringe to identify the cassette.</p><p>In one embodiment, the cassette identification means comprises at least one protrusion.</p><p>In the device according to one form, a detector for reading a cassette identification means and identifying a cassette is provided.</p><p>The present application further relates to a device for injecting a therapeutic agent. The device comprises an automated syringe and a disposable cassette for use with the syringe, the cassette being located in the housing and in a sleeve that is movable between the first and second positions and in the sleeve. It comprises a syringe arranged in the syringe and a shield remover extending through an opening at the base end of the housing to remove the needle shield from the syringe.</p><p>The present application further relates to disposable cassettes for use with automated syringes. The cassette is a housing and a sleeve that is located within the housing and is movable between the first and second positions, the sleeve from which the syringe can be placed, the sleeve and the needle shield. It comprises a shield remover that extends through an opening at the base end of the housing for removal from the syringe.</p><p>The accompanying drawings show preferred embodiments of the present application and are rather exemplary rather than limiting.</p>

<figref num="1">FIG. 5 is a side view showing an automated injection device 100 including an automated syringe 300 and a cassette 200 according to an exemplary embodiment.</figref><figref num="2A">An exploded perspective view showing a cassette 200 according to an exemplary embodiment, wherein the cassette comprises an outer housing 210, an inner sleeve 220, a syringe 260, a lock cap 230, a cover 250 and a shield remover 240. It is a perspective view.</figref><figref num="2B">Top-to-bottom front perspective showing the cassette 200, showing the side wall 211 of the outer housing 210, the window 212 of the outer housing 210, the pins 215 of the outer housing 210 and the shield remover 240. It is a front perspective view.</figref><figref num="2C">Cross-sectional side view showing the cassette 200, including barrel 261, fluid chamber 262, predetermined dose formulation 267, injection needle 265, outwardly extending flange 263, non-rigid protective needle shield 266, and movable plunger stopper. FIG. 6 is a cross-sectional view showing a syringe 260 with 264 and a shield remover 240 with a cantilever spring member 247 and a protrusion or tab 248.</figref><figref num="3A">It is a front perspective view from the bottom to the top showing the cassette 200, and is a front perspective view showing the outer housing 210 of the cassette including the bottom surface 210B having the protrusion 210P.</figref><figref num="3B">FIG. 3A is a bottom view showing the cassette, wherein the outer housing 210 of the cassette, the projecting portion 210P, the bottom surface 210B, and the latch mechanism 218 including a pair of elastic lock arms 218a and 218b extending in parallel are provided. It is a bottom view which shows the lock claw slots 219a and 219b, and the pin 268 of the inner sleeve.</figref><figref num="4A">A rear perspective view showing a shield remover 240 according to an exemplary embodiment, showing a cantilever spring member 247 and a protrusion or tab 248, wherein the shield remover 240 has a hollow body 241 and a closed end. It has a portion 242, an open end portion 243, a substantially cylindrical portion 241T of the main body 241 and a substantially rectangular key portion 241K of the main body 241 and a plurality of flexible tongue portions 245T extending outward. A deployable partial collar structure 245, an outwardly extending flange or grip member 244 with parallel sides 244S and both ends 244E, a bottom wall portion 241 of the key portion 241K, and an inclined locking surface of the protrusion or tab 248. It is a rear perspective view provided with 248S.</figref><figref num="4B">A front perspective view showing a shield remover 240 according to another exemplary embodiment, wherein the grip member 244, the closed end 242 of the body 241, the cantilever spring member 247, and the protrusion or tab 248. And the tilted lock surface 248S of the protrusion or tab 248 and the key portion 241K of the body 241 and the shield remover 240 has a metal tubular insert 246 with a needle shield gripping tooth portion 246T and a cylindrical body portion. It is sectional front perspective view which comprises the inner surface 241I of 241T.</figref><figref num="4C">FIG. 6 is a cross-sectional side view showing a shield remover 240 according to another exemplary embodiment, comprising a grip member 244, a closed end 242 of the body 241, a cantilever spring member 247, and a protrusion or tab 248. The slanted lock surface 248S of the protrusion or tab 248, the key portion 241K of the body 241 and the inner surface 241I of the cylinder-shaped body portion 241T are shown, and the shield remover 240 is replaced by the needle shield gripping tooth portion 246T. It is a cross-sectional side view provided with'.</figref><figref num="4D">FIG. 2B is a rear perspective view showing a part of the cassette 200 from the bottom to the top, in which the shield remover 240, the outer housing 210 of the cassette, the protrusion 210P, and the bottom surface 210B of the outer housing are shown. FIG. 3 is a rear perspective view showing the aperture 210A of the outer housing and the protrusion or tab 248 of the shield remover.</figref><figref num="4E">A bottom-to-top front perspective showing a portion of the cassette 200 from which the shield remover 240 has been removed from the cassette 200, with the deployable partial collar structure 245 of the shield remover 240 and the outer casing of the cassette. It is a front perspective view showing the aperture 214A of the body 210, the bottom wall portion 210B of the outer housing, and the aperture 210A of the outer housing 210.</figref><figref num="4F">It is a cross-sectional side view showing a part of a cassette 200, which is the inner sleeve 220, the outer housing 210, the end wall portion 214 of the outer housing, the aperture 214A of the outer housing, the shield remover 240, and the like. 2 is a cross-sectional side view showing an injection needle 265, a needle shield 266, a cantilever spring member 247, a protrusion or tab 248, and an outer housing aperture 210A.</figref><figref num="4G">It is a cross-sectional side view showing the cassette 200 installed in the automatic syringe 300, the shield remover 240, the tab 248 of the shield remover 240, the needle shield 265, the outer cassette chassis 210, and the outside. It is a side sectional view showing the bottom wall portion 210 of the housing, the aperture 210A of the outer cassette housing 210, the chassis 301 of the automatic syringe 300, and the pin P provided in the chassis 301.</figref><figref num="4H">It is a cross-sectional side view which shows the cassette 200 installed in the automatic injector 300, which is the shield remover 240, the needle shield 265, the outer cassette housing 210, the bottom wall portion 210B of the outer housing, and the outer cassette. It is sectional drawing which shows the aperture 210A of the housing 210, the protrusion 210P, the detector 370, the chassis 301 of an automatic syringe, and the pin P.</figref><figref num="5A">It is a front perspective view which shows the lock cap 230 which concerns on an exemplary embodiment, and this lock cap is an annular body 231, an outer surface 231O, an inner surface 231I, both arm parts 232, a cutout member 233, and a hook. FIG. 3 is a front perspective view including a shaped end portion 234, a soft elastic ring-shaped bumper 235, and an opening portion 236.</figref><figref num="5B">It is a rear perspective view showing a part of the inner sleeve 220 of the cassette 200, and is a rear perspective view of the syringe 260, the inner sleeve 220, the lock cap 230, the annular body 231 of the lock cap, the outer surface 231O of the lock cap, and the lock cap. Both arms 232, lock cap cutout member 233, lock cap soft elastic ring bumper 235, lock cap opening 236, prefilled syringe 260 flange 263, and inner sleeve 220. It is a rear perspective view which shows the receiving part 220R.</figref><figref num="5C">A side view showing a portion of the inner sleeve 220 into which the syringe 260 is inserted and locked in place using the lock cap 230, the annular body 231 of the lock cap, the outer surface 231O of the lock cap, and Both arms 232 of the lock cap, the cutout member 233 of the lock cap, the soft elastic ring-shaped bumper 235 of the lock cap, the flange 263 of the prefilled syringe 260, and the double receiving receiving part 220R of the inner sleeve 220. , Is a side view.</figref><figref num="5D">A front perspective view showing a portion of the inner sleeve 220 and a lock cap with reference numeral 230'according to another embodiment, wherein the lock cap is an annular body 231, both arms 232, and a hook-shaped means. It is a front perspective view provided with 234'.</figref><figref num="6A">An anterior elevation view showing an automated syringe 300 in an exemplary embodiment, wherein the automated syringe comprises a case 302, a handle section 304, a handle 305, a cassette receiving section 306, and a cassette door 308. FIG. 3 is a front elevation view comprising a user interface 312, a speaker aperture 314, a speed selection switch 316, and an end wall portion 318.</figref><figref num="6B">A first side elevation view showing the automatic syringe 300 of FIG. 6A, wherein the case 302, the handle section 304, the handle 305, the soft grip area 305S, the cassette receiving section 306, the cassette door 308, and the window. It is a first side elevation view which shows the part 310A, the user interface 312, the setting / mute switch 315, the speed selection switch 316, and the end wall part 318.</figref><figref num="6C">A rear elevation view showing the automatic syringe 300 of FIG. 6A, wherein the case 302, the handle section 304, the handle 305, the soft grip area 305S, the cassette receiving section 306, the windows 310A and 310B, and the ends. It is a rear elevation view which shows the wall part 318.</figref><figref num="6D">A second side elevation view showing the automatic syringe 300 of FIG. 6A, wherein the case 302, the handle section 304, the handle 305, the soft grip area 305S, the cassette receiving section 306, the cassette door 308, and the window. It is a second side elevation view which shows the part 310B, the user interface 312, the take-out button 317, the speed selection switch 316, and the end wall part 318.</figref><figref num="6E">6A is an elevation view showing the first end of the automatic syringe 300, showing the end wall 318, the target light 320, the cassette door aperture 308A, and the skin sensor 380. be.</figref><figref num="6F">FIG. 6A is an elevation view showing the second end of the automatic syringe 300 of FIG. 6A, showing the start button 307.</figref><figref num="7">FIG. 3 is a phase diagram showing a decision logic for controlling a skin sensor 380 using a microprocessor 350 of an automatic syringe 300 in one embodiment of the present application.</figref><figref num="8">It is a cross-sectional side view which shows the automatic injection device 100, and shows the automatic syringe 300 and the cassette 200, and the automatic syringe 300 is a chassis 301, a case 302, a motor drive type insertion drive part 330, and a motor drive type. FIG. 6 is a cross-sectional side view comprising an extrusion drive unit 340, a microprocessor 350, a battery 360, and a cassette comprising a syringe 260.</figref><figref num="9A">It is a flowchart which shows the decision logic for controlling various functions of an automatic syringe using a microprocessor in an exemplary embodiment of the present application.</figref><figref num="9B">It is a flowchart which shows the decision logic for controlling various functions of an automatic syringe using a microprocessor in an exemplary embodiment of the present application.</figref><figref num="10A">A top-to-bottom side perspective showing a motor-driven insert drive unit 330 according to an exemplary embodiment, wherein the insert drive unit includes an insert drive motor 331, a drive link or rack 332, and a plurality of gears. 333₁、333₂、333₃、333₄Insertion drive gear train 333 with, top rack surface 332T, bottom rack surface 332B, and spaced first and second protrusions 332.₁And 333₂It is a side perspective view provided with the rack tooth portion 334.</figref><figref num="10B">It is a side view from the bottom to the top which shows the motor drive type insertion drive part 330 which concerns on an exemplary embodiment, and this insertion drive part includes an insertion drive motor 331, a drive link or a rack 332, and a plurality of gears. 333₁、333₂、333₃、333₄Insertion drive gear train 333 with, top rack surface 332T, bottom rack surface 332B, and spaced first and second protrusions 332.₁And 333₂It is a side perspective view provided with the rack tooth portion 334.</figref><figref num="11A">It is an exploded perspective side view which shows the plunger rod 342, the lead screw 343 and the nut 345 of the motor drive type extrusion drive part which concerns on an exemplary embodiment, and is the pusher 342P of a plunger rod 342, the end face 342EF of a plunger rod 342, and a nut. It is an exploded perspective view which shows the inner thread 345T of 345, the outer thread 343T of a lead screw 343, and the holder 345H of a nut 345.</figref><figref num="11B">11B is a perspective side view of the assembled state showing the plunger rod 342, the lead screw 343, and the nut 345. The pusher 342P of the plunger rod 342, the end face 342EF of the plunger rod 342, the internal thread 345T of the nut 345, and the lead screw. It is a perspective side view which shows the external thread 343T of 343 and the holder 345H of a nut 345.</figref><figref num="11C">It is a perspective view which shows a part of the motor drive type extrusion drive part 240, which is the extrusion drive motor 341, the plunger rod 342, the lead screw 343, the gear train 344 of the extrusion drive part, pusher 342P, nut 345, and External thread 343T for lead screw 343, holder 345H for nut 345, and multiple gears 344 in the gear train of the extrusion drive.₁、344₂、344₃、344₄、344₅、344₆It is a perspective view which shows.</figref><figref num="12">It is an anterior elevation view showing the automated syringe 300 according to the exemplary embodiment, wherein the automated syringe shows the progress LED 550 of the user interface 312.</figref><figref num="13">It is an anterior elevation view showing an automated syringe 300 according to an exemplary embodiment, wherein the automated syringe shows various exemplary icons presented by user interface 312.</figref>

FIG. 1 shows a front view of the automatic injection device 100 in the exemplary embodiment according to the present application. The automated injection device 100 includes an automated syringe 300 and a cassette 200. The automatic syringe 300 comprises a cassette door 308, which is in an open position, allowing the cassette 200 to be inserted (as shown), and the cassette door is in a closed position (eg, FIG. In 6B), the cassette 200 is aligned with the insertion and extrusion drive units 330 and 340 of the automatic syringe 300 (FIG. 8), respectively. The automated syringe 300 is structured and configured for handheld operation and is reusable. The cassette 200 is structured and configured to accommodate and protect the syringe 260 (eg, FIG. 2A), which is pre-filled with a predetermined dose of pharmaceutical product. The cassette 200 assists and enables easy use of the syringe with the automated syringe 300 and prevents the needle from sticking before and after use. Further, the cassette 200 may be structured and configured for single, disposable use.

FIG. 2A shows an exploded perspective view of the cassette 200 according to an exemplary embodiment of the present invention. The cassette 200 includes an outer housing 210, an inner sleeve 220 that is slidable within the outer housing 210, a syringe 260 that is located within the inner sleeve 220 or is held by the inner sleeve 220, and a syringe 260. It is equipped with a shield remover 240 for removing the protective needle shield 266. The outer housing 210 includes a base end wall portion 214 and an opening tip portion 216. The base end wall portion 214 of the outer housing 210 has an aperture 214A sized and shaped to receive the shield remover 240 through it. The inner sleeve 220 includes a base end wall portion 222 and an opening tip portion 224. The base end wall 222 of the inner sleeve 220 has an aperture 222A sized and shaped to receive the approximately needle shield 266 of the syringe 260 through it. The cassette 200 further comprises a lock cap 230 for closing the opening tip 224 of the inner sleeve 220 and locking the syringe 260 into the inner sleeve 220. The cassette 200 further comprises a cover 250 for closing the opening tip 216 of the outer housing 210. The cover 250 provides an unauthorized opening prevention function by wrapping the inner sleeve 220 and the syringe 260 containing the pharmaceutical product 267 inside the outer housing 210 of the cassette 200, and similarly achieves the superficial appearance of the cassette 200. Let me.

FIG. 2B shows a perspective view in which the front of the cassette 200 is lowered. The outer housing 210 of the cassette 200 comprises an elongated opening or window 212 at each side wall 211 thereof. The window portions 212 are arranged on opposite sides of each other and are aligned with each other. Further, the inner sleeve 220 of the cassette 200 is made of a translucent hard material such as clear polycarbonate. The window 212 on the side wall 211 of the outer housing 210, in combination with the translucent inner sleeve 220, allows the syringe 260 housed in the inner sleeve 220 to be visible (FIG. 2C). The wall portion of the inner sleeve 220 visible through the window portion 212 of the outer housing 210 comprises a filling capacity indicator (not shown). The outer housing 210 of the cassette 200 also has a pin 215 or other suitable mechanical structure, which pin or mechanical structure inside the cassette door 308 with the cassette 200 in the wrong direction and / or orientation. Prevents insertion into. The "arrow" icon is formed on the shield remover 240 or the outer housing 210 (not shown) and indicates the exact direction and orientation of the cassette to be inserted into the cassette door 308.

FIG. 2C shows a side sectional view of the cassette 200. As can be seen, the inner sleeve 220 comprises a pin 268 of the inner sleeve, which is engaged by the insertion drive 330 of the automated syringe 300 during operation of the automated syringe. Driven by the insertion drive 330, the pin 268 moves the inner sleeve 220 inside the outer housing 210 of the cassette 200. The inner sleeve 220 is sized and shaped to receive the syringe 260 in it.

Still referring to FIG. 2C, the syringe 260 comprises a barrel 261 that defines the fluid chamber 262. The fluid chamber 262 is pre-filled with a predetermined dose of drug 267. The drug 267 has a viscosity corresponding to the temperature of the drug 267. The syringe 260 comprises a removable or fixed injection needle 265 at the proximal end of the barrel 261 and an outwardly extending flange 263 located at the distal end of the barrel 261. The needle 265 communicates with the fluid chamber 262 to allow delivery of a predetermined dose of drug 267 discharged from the fluid chamber 262 of the syringe barrel 261. The syringe 260 further comprises a movable plunger stopper 264, which is placed in the fluid chamber 262 of the barrel 261 to expel a predetermined dose of the drug 267 from the chamber 262, so that the drug is injected. Distributed through needle 265. The protective needle shield 266 described above covers the injection needle 265 and is made of a non-rigid material. In one exemplary embodiment, the syringe 260 may be a standard 1 ml glass syringe. The lock cap 230 closes the tip 224 of the inner sleeve 220 and places the base end 261P of the syringe barrel 261 against the inner edge at the junction between the inner surface of the base end wall 222 and the aperture 222A of the inner sleeve 220. Immobilization, thus the syringe 260 moves with the inner sleeve 220 as the inner sleeve advances within the outer housing 210 during the operation of the automatic syringe 300.

Referring to FIGS. 3A and 3B, the outer housing 210 of the cassette 200 comprises a cassette identification means, which is the information that identifies the cassette 200, eg, the contents of a syringe 260 housed in the cassette 200. Provide information about objects and / or other cassette / syringe properties. In one exemplary embodiment, the cassette identification means comprises one or more ridges or protrusions 210P provided on the bottom surface 210B of the outer housing 210 of the cassette 200. As shown in FIGS. 4G and 4H, the protrusion 210P is detected by the detector 370 inside the automatic syringe 300 when the cassette 200 is inserted into the door 208 of the automatic syringe 300 and the door 208 is closed. Or engage the detector 370. The detector 370 is electrically coupled to a microprocessor (eg, the microprocessor 350 shown in FIG. 8) housed in the automatic syringe 300, wherein the automatic syringe 300 is a cassette identification means. Reads, thereby making it possible to identify the cassette 200. In one exemplary embodiment, a predetermined number of protrusions 210P are located at predetermined positions on the bottom surface 210B of the outer housing 210, and the detector 370 comprises a keypad consisting of a plurality of keys (not shown). Certain of the keys are activated by the cassette protrusion 210P, depending on the location and number of protrusions 210P, when the cassette 200 is inserted into the automatic syringe 300. Each key activated by one of the protrusions 210P provides information that allows the automated syringe 300 to identify the cassette 200. In some embodiments, the cassette identification means identifies the drug delivery profile of the drug delivered to the cassette 200. Therefore, when a valid cassette is inserted and the valid cassette and the information provided by the cassette identification means are recognized, the available preset drug efflux rate range corresponding to the drug delivery profile of the drug delivered within the cassette 200 is , To the automatic syringe 300 It will be registered more automatically. The available speed range depends on the drug properties such as syringe filling volume and viscosity. As a non-limiting example, if the cassette identification means comprises multiple protrusions 210P, one protrusion indicates a 1 mL filling, two protrusions indicate a 0.5 mL filling, and additional protrusions indicate drug and / Or provided to identify characteristics.

FIG. 3B also shows a latch mechanism 218, which is provided on the bottom wall portion 210B of the outer housing 210 of the cassette 200. The latch mechanism 218 extends in parallel with a pair and has elastic locking arms 218a, 218b. The lock arm portions 218a and 218b define the lock return slots 219a and 219b separately. Pin 268 of the inner sleeve 220 engages the return slots 219a, 219b of the latch mechanism 218 when the syringe 260 is in the home position and the injection needle 265 of the syringe 260 is covered inside the cassette 200 in the needle hiding position. Thereby, the latch of the inner sleeve 220 to a predetermined position in the outer housing 210 of the cassette 200 is locked. During the injection cycle, the insertion drive 330 (FIG. 8) of the automatic syringe 300 spreads the elastic locking arms 218a, 218b apart and the pin 268 of the inner sleeve expands the pin 268 of the inner sleeve to the return slot 219a of the latch mechanism 218. , 219b, which allows the unlatched inner sleeve 220 containing the syringe 260 to be freely moved by the insertion drive 330, which inserts the pin 268 of the inner sleeve. Press and move the inner sleeve 220 with respect to the outer housing 210 from the home position where the injection needle 265 is in the needle hiding position to the injection position where the injection needle 265 is in the needle extension position and inject at this needle extension position. Allows the needle to penetrate the skin in place. At the end of the injection cycle, the insertion drive 330 pulls the pin 268 of the inner sleeve back into the retaining slots 219a, 219b, thereby reaching the home position where the needle 265 is in the needle hiding position (syringe 260). (Accommodates) Inner sleeve 220 is restored.

Cassettes similar in structure and operation are described in more detail in patent applications (Patent Documents 1-3) and are incorporated herein by reference in their entirety.

The shield remover 240 shown in FIGS. 4A-4F grips the protective needle shield 266 (FIG. 2C) that covers the injection needle 265 of the syringe 260, so the shield remover 240 is used to remove the needle shield 266. Allows you to use. Further, the shield remover 240 engages the cassette 200 in a locked manner and is therefore not easily withdrawn from the cassette 200 unless the cassette 200 is accurately mounted on the automatic syringe 300. This feature prevents the needle shield 266 from being accidentally removed. In addition, the presence of the shield remover 240 provides an indication that the cassette 200 has not been previously used and has not been tampered with.

As shown in FIG. 4A, in one exemplary embodiment, the shield remover 240 comprises a hollow body 241 with a closed end 242 and an open end 243. The hollow body 241 comprises a substantially cylindrical portion 241T and a substantially rectangular, key-shaped portion 241K, the key-shaped portion extending outward from one side of the cylinder-shaped portion 241T. The open end 243 of the cylindrical portion 241T has, for example, a plurality of flexibility and defines the expandable partial collar structure 245 formed by the outwardly projecting tongue portion 245T. The cylinder-shaped portion 241T of the main body 241 narrows in a taper shape toward its closed end portion 242. The flange extending outward functions as a gripping member 244 and is defined at the closed end portion 242 of the cylinder-shaped main body portion 241T. The grip member 244 comprises a flat parallel side surface 244S connecting the rounded ends 244E. The grip member 244 allows a user with manual dexterity to easily remove the needle shield 266 from the syringe 260 after the cassette 200 has been accurately mounted on the automatic syringe 300.

As shown in FIG. 4B, in some embodiments, the shield remover 240 comprises a metal tubular insert 246 frictionally engaged with the inner surface 241I of the cylindrical body portion 241T of the body 241. The metal insert 246 has a slit (not shown) along its length and is provided with a needle shield gripping tooth portion 246T spaced by two or more, the needle shield gripping tooth portion of the cylinder-shaped main body portion 241T. It projects inwardly inward, towards its closed end 242 as a whole. In another exemplary embodiment, as shown in FIG. 4C, the needle shield grip tooth portion 246T'is formed on the inner surface 241I of the cylinder-shaped body portion 241T.

As shown in FIGS. 4A-4C, the key-like body portion 241K of the shield remover 240 prevents the shield remover 240 from rotating within the base end wall 214 of the outer housing 210 of the cassette 200. .. The key-like body portion 241K comprises a bottom wall portion 241W, which is formed by a cantilever spring member 247 and a downwardly extending protrusion or lock tab 248 provided at the free end of the spring member 247. It has a locked structure. The lock tab 248 comprises an undercut portion formed by an inclined surface 248S, which faces the closed end 242 of the cylindrical body portion 241T and defines an acute angle θ with the outer surface 247O of the cantilever member 247.

FIG. 4F shows a side sectional view of the base end portion of the cassette 200. As shown, the needle cover 266 of the syringe 260 is located within the cylindrical body portion 241T (FIG. 4A) of the shield remover 240, so that the needle grip tooth portion 246T (or or) of the shield remover 240 is located. The tooth portion 246T') shown in FIG. 4C grips the outer surface of the needle cover 266. The main body 241 of the shield remover 240 extends through the aperture 214A formed on the base end wall portion 214 of the outer housing 210 of the cassette 200, and this aperture extends the gripping member 244 of the shield remover 240. Positioned on the outside of the cassette 200. The lock structure of the shield remover 240 formed by the cantilever spring member 247 and the lock tab is located within the peripheral base end portion of the outer cassette housing 210, so that the lock structure prevents unauthorized opening. The shield remover 240 is locked in a predetermined position in the cassette 200. Locking is facilitated by a cantilever spring member 247, which pushes or urges the tab 248 into the lock aperture 210A (best illustrated in FIGS. 4D and 4E). This lock aperture is defined on the bottom surface 210B of the outer housing 210 of the cassette 200. The lock tab 248, which engages with the lock aperture 210A of the outer housing 210 of the cassette, largely prevents the shield remover 240 from being pulled out of the cassette 200 as long as it is correctly installed inside the cassette 200 automated syringe 300. Since the shield remover 240 is attached to the needle shield 266 and locked in the cassette 200, the needle shield 266 is not abruptly removed from the syringe 260 before the automatic syringe 300 is installed correctly. The presence of the shield remover 240 also provides an indication that the cassette 200 has not been previously used and has not been tampered with.

FIG. 4G is a side sectional view of the cassette 200 installed on the access door of the automatic syringe (both not shown) before closing the door, and FIG. 4H is the access door of the automatic syringe (both not shown). It is a side sectional view of the cassette 200 after the door is already closed. As shown in FIGS. 4G and 4H, the automated syringe 300 has a chassis 301 (also see FIG. 8) for holding the cassette 200 within the automated syringe 300. Chassis 301 has a pin P and a cassette identification detector 370. As shown in FIG. 4H, when the access door is closed, the cassette 200 is positioned in or on the chassis 301 of the automatic syringe 300, so that the cassette identification protrusion 210P is read by the detector 370 and thereby. It is possible to automatically identify the cassette 200. The pin P also pushes the lock structure tab 248 of the shield remover 240 upward, thereby overcoming the urging force provided by the cantilever spring member 247. As the lock tab 248 moves upwards, it releases the tab receiving aperture 210A (FIG. 4F) on the bottom wall 210B of the outer cassette enclosure 210, thereby locking the shield remover 240 from the outer enclosure 210 of the cassette 200. To release. With the lock structure of the shield remover 240 unlocked, the user now grabs the grip member 244 of the shield remover 240 and pulls it out of the cassette 200 and the automatic syringe 300, thereby needle shield 266. Remove and uncover the needle 265.

FIG. 4E shows a front perspective view from the bottom to the top of the base end portion of the cassette 200 with the shield remover 240 removed from the cassette 200. As shown, once the shield remover 240 is removed, the tongue 245T of the deployable partial collar structure 245 unfolds or expands outwards and the shield remover 240 and needle shield 266 attached to it. (Not shown) is prevented from being reinserted into the aperture 214A formed on the base end wall portion 214 of the outer housing 210 of the cassette. Therefore, without the shield remover 240, the user is provided with an indication that the cassette 200 is already in use or has been tampered with.

The lock cap 230 shown in FIGS. 5A-5C locks the syringe 260 into the inner sleeve 220 with a predetermined force, which is set during assembly of the cassette 200. The lock cap 230 includes an overall flat annular body 231 having an outer surface 231O and an inner surface 231I, and both arm portions 232 suspended from the body 231 so as to be separated from the inner surface 231I. Each arm 232 comprises a cutout member 233 having a hook-shaped end 234. In some embodiments, the cutting member 233 may be spring-shaped. The member 233 extends outward from the arm portion 232 toward the main body portion 231. The body portion 231 is formed of a metal or hard plastic material. The ring-shaped bumper 235 of the soft elastomer is attached to the inner surface 231I of the main body 231. The main body 231 and the bumper 235 define an opening 236, which is actuated by a motor driven extrusion drive 340 (FIG. 11C) of the automated syringe 300 during operation of the automated syringe 300. The plunger rod 343 is sized to pass through the lock cap 230 and engage the plunger stopper 264 to allow the plunger stopper to move through the fluid chamber 262 of the syringe barrel 261. The lock cap 230 is sized to receive the flange 263 of the syringe 260 between its arms 232 in a slip-fitting manner in which the bumper 235 engages the top surface 263T of the flange 263 as shown in FIGS. 5B and 5C. It is attached. The arm portion 232 of the lock cap 230 is inserted into the facing receiving portion 220R formed at the tip of the inner sleeve 220 when the syringe 260 is incorporated into the inner sleeve 220. The hook-shaped portion 234 of the arm portion 232 grips the inner surface of the receiving and receiving portion 220R and locks the lock cap 230 in place, thereby locking the syringe 260 into the inner sleeve 220. The arm 232 of the lock cap 230 is inserted within the receptacle 220R of the inner sleeve 220 for the selected distance.

FIG. 5D shows a lock cap in another embodiment labeled with reference numeral 230'. The lock cap 230'is similar to the lock cap 230 of FIGS. 5A to 5C, but the cutting member 233 is omitted, and instead, a hook-shaped means 234'is provided at the end of each arm portion 262. Has been done.

Here, referring to FIGS. 2A to 2C, the cover 250 is attached to the tip of the outer housing 210 of the cassette 200. The cover 250 is a substantially planar member having a shape that matches the shape of the tip portion 216 of the outer housing 210. The cover 250 comprises two or more locking arms 253, the corresponding receiving portions extending from the inner surface 251 of the cover 250 and extending through the sidewall 211 of the outer housing 210. Locks into 255. Also, adjacent to its tip 216, it covers a dentate structure or other suitable locking means (not shown) formed within the outer housing 210, on the outer housing, or through the outer housing 250. May be used to attach. The cover 250 further comprises an opening 254, which is axially aligned with the opening 236 defined by the lock cap 230. The opening 254 in the cover 250, like the opening 236 of the lock cap 230, is actuated by the motor driven extrusion drive 240 (FIG. 8) of the automatic syringe 300 during operation of the automatic syringe 300. The plunger rod 342 is sized to pass through the cover 250 and engage with the plunger stopper 264 to allow the plunger stopper to move through the fluid chamber 262 of the syringe barrel 261.

Now referring to FIGS. 6A-6F, the automated syringe 300 comprises a casing 302 having a handle section 304 and a cassette receiving section 306 along the handle section 304. To assist patients with manual dexterity, the handle section 304 of the casing 302 of the automatic syringe defines an ergonomically shaped handle 305 with a soft grip area 305S. The cassette receiving section 306 comprises the cassette door 308 (FIGS. 6B and 6D) described above. The cassette door receives the cassette 200 in the open position (FIG. 1) and aligns the cassette 200 with the insertion and extrusion drive and other structures and components of the automatic syringe 300 in the closed position. The cassette door 308 has a "cassette" icon, which indicates an insertion entry point for the cassette 200. The cassette receiving section 306 of the casing 302 is provided with windows 310A and 310B on both sides thereof, and these windows are the windows of the cassette 200 when the cassette door 308 is closed with the cassette 200 accurately inserted therein. Align with 212 (Fig. 2B). In one or more embodiments, the windows 310A and 310B have a double layer. One or more light emitting portions (not shown) are provided inside the casing 302 to evenly illuminate the window portion 212 of the cassette and the syringe 260 located in the inner sleeve 220 of the cassette 200, and thus the user. Can observe the injection cycle through the windows 310A, 310B of the automatic syringe 300, i.e., the initial and end positions of the plunger stopper 264 of the syringe 260 during the syringe contents (hereinafter "drug" extrusion process. And the movement of the syringe in the cassette 200 can be observed.

Still referring to FIGS. 6A, 6B, 6D and 6F, the automated syringe 300 further comprises a user interface 312 and a voice speaker (not shown). The user interface 312 (most commonly shown in FIG. 6) is located in the cassette receiving section 306 of casing 302 and provides a variety of visual indications. The audio speaker is located inside the casing 302 to provide a variety of audio displays. The audio speaker communicates audio with the external environment via a speaker aperture 314 formed in the casing 302 in the cassette receiving section 306. Visual and audio displays generated by the user interface 312 and audio speakers inform the user when the automated syringe 300 is ready for use, the progress of the injection process, the completion of the injection, the occurrence of an error and other information. The automated syringe 300 further comprises one or more of a setting / mute switch 315, a speed selection switch 316, a start button 307 and an eject button 317. The setting / mute switch 315 (FIG. 6B) is located in the cassette receiving section 306 of casing 302. The mute switch 315 is structured and configured to allow the user to turn on and off all synthetic sounds except error sounds and to react in real time, so that the user can When the injection process is started and the mute switch is turned off, the sound is immediately muted. The mute switch 315 is similarly structured and configured to slide towards the "mute" icon and mute the audio speaker. The light emission display may be provided to confirm the "silenced" state. The speed selection switch 316 (FIGS. 6A and 6B) is located in the cassette receiving section 306 of the casing 302. The speed selection switch 316 is structured and configured to allow the user to choose from a plurality of preset drug delivery (extrusion) speeds to suit the individual preference of the patient. .. There are three speed selection switches 316 It has a switch position of. The speed selection switch according to the other embodiment may have two switch positions or four or more switch positions. In still other embodiments, the speed selection switch may be of infinitely variable type. In some embodiments, changing the position of switch 316 prior to injection changes the drug extrusion rate during injection, while changing the position of speed selection switch 316 during injection is injection in real time. Do not change the speed. The automated syringe 300 is also provided with one or more demonstration cassettes, allowing the user to experiment at different drug delivery rates. The start button 307 is provided at the free end of the handle 305. The button 307 has an uneven portion 307I for optimizing the placement of the thumb on the button 307. The button 307 is made of a translucent material, which allows for a lighting effect that illuminates the button as a signal. The eject button 317 (FIG. 6D) is located in the cassette receiving section 306 of the casing 302. The eject button 317 has an uneven portion 317I for optimizing the placement of a finger on the button 317. In some embodiments, the eject button 317 is controlled by a microprocessor of the automatic syringe 300 (eg, microprocessor 350 shown in FIG. 8), which eliminates unexpected inputs during the injection process. Is programmed to. Is possible. The start button 307 is provided at the free end of the handle 305. The button 307 has an uneven portion 307I for optimizing the placement of the thumb on the button 307. The button 307 is made of a translucent material, which allows for a lighting effect that illuminates the button as a signal. The eject button 317 (FIG. 6D) is located in the cassette receiving section 306 of the casing 302. The eject button 317 has an uneven portion 317I for optimizing the placement of a finger on the button 317. In some embodiments, the eject button 317 is controlled by a microprocessor of the automatic syringe 300 (eg, microprocessor 350 shown in FIG. 8), which eliminates unexpected inputs during the injection process. Is programmed to. Is possible. The start button 307 is provided at the free end of the handle 305. The button 307 has an uneven portion 307I for optimizing the placement of the thumb on the button 307. The button 307 is made of a translucent material, which allows for a lighting effect that illuminates the button as a signal. The eject button 317 (FIG. 6D) is located in the cassette receiving section 306 of the casing 302. The eject button 317 has an uneven portion 317I for optimizing the placement of a finger on the button 317. In some embodiments, the eject button 317 is controlled by a microprocessor of the automatic syringe 300 (eg, microprocessor 350 shown in FIG. 8), which eliminates unexpected inputs during the injection process. Is programmed to.

Referring again to FIG. 6E, the cassette receiving section 306 and the cassette door 308 of the casing 302 form the proximal wall portion 318 of the automated syringe 300. The base wall 318 is wide, flat and stable for easy positioning of the automatic syringe 300 on the support surface after removal of the shield remover 240 or when the automatic syringe 300 does not contain the cassette 200. It is configured as a base. Part of the base wall portion 318 formed by the cassette door 308 has an aperture 308A, which, when the cassette 200 is installed in the automatic syringe 300, removes the shield remover 240 from the cassette 200. It is sized and shaped so that it can be pulled out through the aperture 308A. As soon as the shield remover 240 passes out through the aperture 308A, the tongue 245T of the deployable partial collar structure 245 expands or expands outwards, thereby the shield remover 240 and its attachment. Prevents the removed needle shield 266 from being reinserted into the aperture 308A of the cassette door 308. The base wall of the automated syringe 300 further comprises a target light 320. The target light 320 is configured and configured to light up when the shield remover 240 is removed from the cassette 200 and pulled out through the aperture 308A, thereby removing the shield remover 240. Is shown visually. Once lit, the target light assists the user in visualizing and selecting the injection site.

Still referring to FIG. 6E, the automated syringe 300 further comprises a volume-based skin sensor 380 (shown by a dashed line). The skin sensor 380 determines when the proximal wall 318 of the automated syringe 300 touches or touches the skin without the need to apply downward pressure to the injection site area. The skin sensor 380 is configured and configured to notify the user via audio and visual indications generated by the speaker and user interface when it detects skin contact. In some embodiments, the skin sensor 380 comprises two pads or electrodes (not shown) embedded in the proximal wall 318 of the automated syringe 300. Touching the electrode increases its capacitive signal. If it is determined that the increase is sufficient by a microprocessor programmed with sensor decision theory (eg, microprocessor 350 shown in FIG. 8), the electrode is activated. To determine if skin contact has been made, the microprocessor reads the capacitance of the electrodes. The microprocessor then processes the capacitance information to determine when both electrodes are no longer in contact with the skin.

FIG. 7 is a phase diagram showing a decision theory for controlling the skin sensor 380 using the microprocessor 350 of the automatic syringe 300 according to the embodiment of the present invention. The process starts with reference numeral 400, which indicates that the automatic syringe is to be reset. The logic then proceeds to state 402, which indicates that the skin sensor is initialized after resetting the automatic syringe. Once initialized, logic proceeds to state 404, which indicates a "non-contact" condition in which the electrodes of the sensor do not touch the skin or only one of the electrodes touches the skin. If both electrodes are in contact with the skin for less than a predetermined threshold period (eg, 1 second), the logic proceeds to state 406, which indicates a "contact" state. If one electrode touches the skin or neither electrode touches the skin, the logic returns to state 404. However, if both electrodes are in contact with the skin for a period equal to the threshold period, the logic proceeds to state 408, which indicates a "contact OK" state. If one electrode touches the skin or the electrode does not touch the skin, the logic proceeds to the "released" state 410. If both electrodes touch the skin, the logic returns to the "contact OK" state 408. If one electrode touches the skin or the electrode does not touch the skin beyond the threshold period (eg, for more than 1 second), the logic returns to the "non-contact" state 404.

FIG. 8 shows a cross-sectional side view of an automated injection device 100 including an automated syringe 100 and a cassette 200 installed therein. The casing 302 of the automatic syringe 300 houses the chassis 301 for receiving the cassette 200, which includes the syringe 206, the motor-driven insertion drive 330, and the motor-driven extrusion drive 340 (described above). It houses the microprocessor 350, the battery 360 for powering the drives 330, 340 and the microprocessor 350, and the skin sensor 380 (described above).

A predetermined instruction is programmed in the microprocessor 350, and this instruction is executed by the microprocessor 350, which makes it possible to control and monitor various operations and functions of the automatic syringe 300. For example, the microprocessor is programmed with instructions to control motor-driven insertion and extrusion drives 330, 340, such as, but not limited to, the microprocessor, injection cycle, and processing flow steps. It controls and monitors, thereby automating needle insertion, drug extrusion and needle retraction, ensuring accurate, consistent and reliable operation of the automated syringe 300 and drug administration. The microprocessor is similarly programmed with instructions to control audio and visual feedback to the user. An automated power-on self-test confirms the operation and remaining charge of the automated syringe 300.

FIG. 9 is a flow chart showing decision logic for controlling various functions of an automated syringe 300 having a microprocessor 350 in an exemplary embodiment of the invention. The microprocessor logic of the automatic syringe starts at block 500 and the automatic syringe is in the "off (cassette) door closed" state. When the user presses the eject button, the microprocessor puts the automated syringe in the "device boot" state in block 502, unless the microprocessor determines that the following error state has occurred, the above error state is 1 ) The automatic syringe is "out of life", that is, the use of the automatic syringe has exceeded a predetermined period (eg 2 years) or a predetermined number of injections (eg 130 injections), 2) irreversible. A device error has occurred, 3) the battery of the automatic syringe has run out, 4) a defective cassette has been inserted into the automatic syringe, or 5) the automatic syringe is below the specified temperature. If any of error states 1-3 occur, the microprocessor executes a visual and audio error message or warning corresponding to blocks 504, 506 and 508, eg, the user interface is for a given period of time (eg 60 seconds). ), The "device malfunction" icon (Fig. 13) flashes rapidly, and the audio speaker produces a predetermined audio indicating a device error. When error condition 4 occurs, the microprocessor executes a visual and audio error message or warning corresponding to block 510, for example, the user interface has a "cassette failure" icon (eg, 60 seconds) over a predetermined period of time (figure). 13) blinks and the audio speaker generates a device error audio. The microprocessor then opens the cassette door after a predetermined period (eg, 2 seconds) and puts the automatic syringe into the "door open, sleep B" state at block 546. When the cassette is removed and the cassette door is closed, the microprocessor puts the automatic syringe in the "off, door closed" state of the block 500. error When state 5 occurs, the microprocessor executes a visual and audio error message or warning corresponding to block 512, for example, the user interface has a "cold" icon (eg, 60 seconds) for a predetermined period of time (Figure 13). Blinks and the speaker raises a device error voice. The microprocessor then returns the automatic syringe to the "off, door closed" state in block 500.

Still referring to Figure 9, if no error condition is detected, the microprocessor puts the automatic syringe in "device boot" at block 502, where the user interface LED is left off and the voice is played by the voice speaker. Do not generate. The microprocessor then opens the cassette door, which puts the automatic syringe into "door open, sleep state A" at block 514. When the cassette is inserted and the cassette door is closed, the microprocessor puts the automatic syringe in the "device apparently activated" state at block 516, where the backlight is turned on and the voice speaker is used to automatically. Generates a voice indicating that the syringe has been activated. When the microprocessor detects a cassette failure detection, it raises a visual and audio error warning in block 518, for example, the user interface has a "cassette failure" icon for a given period of time (eg 60 seconds) (Figure 13). Blinks and the audio speaker generates a device error audio. The microprocessor then opens the cassette door after a predetermined period of time (eg, 2 seconds), putting the automatic syringe into the "door open, sleep B" state of block 546, so that the cassette can be removed. If the cassette door is nearly occluded, the microprocessor puts the automated syringe in the "off, door occluded" state of block 500. When the eject button is pressed, the microprocessor puts the automatic syringe into "door open, sleep A" in block 514. Once the automatic syringe is in the "device apparently booted" state of block 516, removing the cassette shield remover puts the microprocessor in the "cap off" state of block 522, where the target light Turn on and keep the backlight on. However, if the shield remover is not removed after the automatic syringe has entered the "device apparently activated" state of block 516 within a given time period (eg 60 seconds), the microprocessor will use the automatic syringe. Put the block 520 in a "cassette in, sleep" state, where the LEDs are turned off and the speakers are turned off (no audio). Then, when the start or eject button is pressed, the microprocessor returns the automatic syringe to the "device apparently activated" state of block 516. However, if the shield remover has not been removed (after entering the "cassette-in, sleep" state of the block), the microprocessor puts the automatic syringe in the "cap-off" state of block 522, as described above. ..

Still referring to Figure 9, once the target light is turned on in the "cap-off" state of block 522, the base wall of the automatic syringe touches the skin at the injection site, so the skin sensor detects contact with the skin. By doing so, the microprocessor puts the automatic syringe in an "injection ready" state at block 526, where the start button is continuously illuminated with a first predetermined color (eg green) and the user interface (eg green). Figure 12) Turns on all the progress LEDs and uses the speaker to make a sound indicating that the syringe is ready to start the injection cycle, turning off the target light and keeping the backlight on, so , The user can see the progress of the syringe injection. If the skin sensor does not detect skin contact within a given period of time (eg 60 seconds) after entering the "ready for injection" state of block 526, the microprocessor "caps off" the automatic syringe in block 524. Put it in the "sleep" state, where the progress LED 550 (Fig. 12) and the audio speaker are turned off. If the start or eject button is subsequently pressed, the microprocessor puts the automatic syringe in the "cap off" state at block 522, as described above. However, if the skin sensor subsequently detects contact with the skin by pressing the start or eject button, the microprocessor puts the automatic syringe in the "ready for injection" state of block 526, as described above. Then, when the automatic syringe is lifted off the skin, the microprocessor returns the automatic syringe to the "cap-on" state of block 522.

Referring again to FIG. 9, pressing the start button while the automatic syringe is in the "injection ready" state of block 526 puts the microprocessor in the "injection start" state of block 528, where , Change the continuous illumination of the start button to a second predetermined color (eg blue) and leave the backlight and progress LED on. If the microprocessor detects that the needle has not been pushed into the skin, it retracts the needle and visually and audibly warns that the needle does not move in block 530, eg, the user interface has a predetermined period of time (for example, the user interface. The "cassette failure" icon (Fig. 13) flashes for 60 seconds) and the speaker makes an error sound. The microprocessor then opens the cassette door after a predetermined period of time, putting the automatic syringe into the "door open, sleep B" state of block 546. However, when the needle is pushed into the skin, after a predetermined period of time (eg 5 seconds), the microprocessor puts the automatic syringe into the "injection progress" state at block 532, where the start button is , The second predetermined color remains continuously proven, and the backlight and progress LED remain on. When pressing a cassette that is clogged with a plunger, the microprocessor retracts the needle and visually and audibly indicates in block 534 that the plunger does not move, eg, the user interface is for a predetermined period of time (eg 60). The "cassette failure" icon (Fig. 13) flashes for seconds) and the speaker emits an error sound. The microprocessor then opens the cassette door after a predetermined period of time, putting the automatic syringe into the "door open, sleep B" state of block 546. Instead, if the automatic syringe is lifted off the skin beyond an acceptable limit over a given period of time (eg 1 second), the microprocessor retracts the needle and "too far from the skin" at block 536. Visually and audibly indicating an alarm, for example, a user interface is provided for a predetermined period of time (eg).

Returning to block 532 in FIG. 9, as the selected drug injection period elapses, the progress LED550 (FIG. 12) is continuously turned off by the microprocessor to indicate the progress of the injection cycle. Once the injection cycle is complete, the microprocessor retracts the needle, thereby putting the automatic syringe into the "needle retract" state at block 538, where the start button is continuously in the second predetermined color. Illuminate, leave the backlight on, and leave only one of the progress LEDs 550 (Figure 12) on. The microprocessor then partially retracts the plunger rod and fully retracts the needle, thereby putting the automatic syringe into the "injection complete" state shown in block 540, where the start button illumination color is set. Return to the first predetermined color, turn off the backlight and the final progress LED 550 (Fig. 12), and use a voice speaker to generate a voice indicating that the injection has been completed. If the automated syringe is removed from the skin for a predetermined period of time (eg 5 seconds), the microprocessor puts the automated syringe in the "plunger retracted" state of block 542 and exits the start button illumination. The microprocessor then retracts the plunger rod and automatically opens the cassette door at block 544, and the automatic syringe is placed in the "door open, sleep B" state of block 546. Here, the used cassette is removed, the cassette door is closed, and the automatic syringe is put into the "off, door closed" state of the block 500. When the microprocessor detects a low battery in the "automatic door open" state of block 544 (this is because a given number of injections remains, a given number of injections has been made, or a given number of days has passed. The microprocessor provides a "low battery" error warning visually and by blinking the "low battery" icon (Figure 13) on the automatic syringe using the user interface. Show it aloud.

Referring to FIG. 8 again, the motor-driven insertion drive unit 330 executes the needle insertion cycle and the needle retreat cycle. 10A and 10B are a top-to-bottom perspective side view and a bottom-to-top perspective side view showing the motor-driven insertion drive unit 330 according to the embodiment, respectively. The insertion drive unit 330 includes a motor 331 of the insertion drive unit, a drive link or a rack 332, and a plurality of gears 333 for transmitting the rotational motion of the motor 331 of the insertion drive unit to drive the rack 332.₁、333₂、333₃、333₄The gear train 333 of the insertion drive unit having the The rack 332 has a top surface 332T and a bottom surface 332B. The top surface 332T of the rack 332 has the first and second protrusions 332 spaced apart from each other.₁And 333₂Have each. The bottom surface 332B of the rack 332 has a rack tooth portion 334. The rack tooth portion 334 of the rack is the gear 333 of the gear train 333.₄Engage in. First protrusion 332 of rack 332 during the needle insertion cycle₁Unlatches the inner sleeve pin 268 of the inner sleeve 220 of the cassette 200 from the latch 218 (FIG. 3B) of the outer cassette housing 210 and engages the pin 268 of the inner sleeve, then the pin of the inner sleeve. Press 268 to drive the inner sleeve 220 with the syringe 260 forward in the outer housing of the cassette 200 from the home position to the needle extension position, in which in this needle extension position the injection needle 265 of the syringe 260 is the cassette. It extends outward from 200 and is inserted into the skin at the injection site. First protrusion 332 of rack 332 during the needle retreat cycle₂Engages the pin 268 of the inner sleeve and pulls the pin of the inner sleeve to drive the inner sleeve 220 with the syringe 260 backwards into the home position again within the outer housing of the cassette 200. Withdraw the needle 265 of the syringe 260 from the skin at the injection site and return it into the cassette 200 (after extruding the drug), where the needle is in the cassette 200 for safe handling and disposal. Protected and locked. The insertion position and timing of the needle is observed and controlled by the microprocessor 350 of the automatic syringe. When an error occurs, the error is displayed in the user interface 312 (Fig. 6A) with a voice warning from the speaker. The insertion drive 330 allows the automated injection device 100 to deliver the drug under the skin (SC) at a predetermined needle injection depth. The insertion drive 330 moves the inner sleeve 220 / syringe 260 forward toward the mechanical rigid stop inside the outer housing 210 of the cassette 200 to achieve the needle depth parameter. The mechanical rigid stop limits the progression of the syringe 260 in the direction of the patient's skin, ensuring needle depth to the desired preset design. By observing the motion of motor 331, it is possible to detect incomplete needle insertion, which occurs with audio and visual warnings, which is the retreat and end of the injection cycle. cause.

The motor-driven extrusion drive unit 340 shown in FIG. 8 performs a drug extrusion cycle, in which the pharmaceutical product is emptied from the syringe 260. 11A and 11B are perspective side views showing the motor-driven extrusion drive unit 340 in one embodiment. FIG. 11A is an exploded perspective side view showing the plunger rod / drive screw means of the motor-driven extrusion drive unit 340 according to the embodiment. FIG. 11B is a perspective side view of the assembled state showing the plunger rod / drive screw means shown in FIG. 11A. FIG. 11C is a perspective view showing the gear train of the motor-driven insertion drive unit 330 according to the embodiment. The extrusion drive unit 340 includes an extrusion drive motor 341, a plunger rod 342, a lead screw 343, and an extrusion drive gear train 344. The plunger rod 342 is driven by an extrusion drive motor 341 via a lead screw 343 and an extrusion drive gear train 344. As shown in FIGS. 11A and 11B, the plunger rod 342 has a pusher 342P and the lead screw 343 has a nut 345. The nut 345 connects the plunger rod 342 to the lead screw 343. The nut 345 has an internal thread 345T that is screwed into the external thread 343T of the lead screw 343. The nut 345 also has a holder 345H for fixing and holding the pusher 342P of the plunger rod 342. As shown in FIG. 11C, the extrusion drive gear train 344 has multiple gears 344.₁、344₂、344₃、344₄、344₅、344₆Have. Extrusion drive gear train 344 gear 344₁And 344₆Is separately connected to the extrusion drive motor 341 and the lead screw 343, so that the extrusion drive gear train 344 can transmit the rotational motion of the insertion drive motor 331 to drive the lead screw 343. As the lead screw 343 rotates, the nut 345 (screwed with the lead screw 343) moves forward or backward along the lead screw 343 (depending on the direction of rotation of the lead screw), which in turn moves the plunger rod. Drive the 342 forward and backward within the automatic syringe 300. When the plunger rod 342 is moved forward, the end face 342EF of the plunger rod 342 is placed in the cassette 200 and at the same time in the syringe barrel 261 of the syringe 260. The plunger rod 343 then engages the plunger stopper 264 of the syringe 260 and pushes it into the end of the syringe barrel 261 to release a predetermined volume of drug from the syringe 260 during the drug extrusion cycle. The position of the components of the extrusion drive 340 as well as the time associated with drug extrusion is monitored by the microprocessor 350. When an error occurs, the error is indicated on the user interface 312 with an audible alarm. The microprocessor 350 can store a variety of factory-configured drug delivery profiles (stroke, velocity, acceleration). Multiple unique drug delivery profiles relate to the structure of the specific cassette. The cassette identification means in the outer housing 210 of the cassette 200 makes it possible to identify the specific and accurate drug delivery profile for the drug filled by the automatic syringe 300. Upon inserting and recognizing a valid cassette 200, the available preset drug extrusion rate range is automatically registered by the automated syringe 300. The available speed range depends on the characteristics of the drug, such as the full capacity and viscosity of the syringe.

The user selects the desired drug extrusion rate (defined as the time to empty the drug in the syringe 260) from a number of different options for the particular formulation using the rate selection switch 316. Upon initiation of the drug extrusion cycle, the stroke of the plunger rod 342 is controlled and monitored to ensure that the plunger stopper 264 reaches the end of the syringe barrel 261, which ensures that the dose delivery is completed. do. If an error occurs during the extrusion process (for example, the plunger rod cannot achieve a full stroke), the automatic syringe 300 immediately terminates the drug extrusion and retracts the needle back into the cassette 200, both audio and visual. Provide a warning.

The injection cycle may be indicated by both audio and visual signals. The light of the automatic syringe 300 turns off in sequence from the top to the bottom during the injection cycle, indicating the user of the progress of the injection. Upon completion of the injection cycle, the automatic syringe 300 retracts the needle back into the disposable cassette 200 and automatically opens the cassette door 308, allowing the user to remove the cassette 200. The opening of the cassette door 308 also indicates to the user that the injection cycle is complete.

In the event of an error during the injection cycle, the automated syringe 300 is equipped with a variety of audio and visual signals to alert the user (operator or patient) of the error and take appropriate action. To urge.

The battery 360 shown in FIG. 8 is a non-replaceable, non-rechargeable battery. Battery 360 should be able to provide sufficient power over a suitable shelf life and useful life to meet drug delivery requirements. When the automatic syringe 300 is activated, it automatically performs a power-on self-test to ensure that sufficient battery power is obtained over a successful injection cycle. In the event of an abnormality in the battery 360 prior to injection, the user interface 312 of the automated syringe 300 provides visual and audio alerts. The microprocessor 350 may be programmed to disable the automated syringe 300 at the end of a predetermined useful life.

The syringe 260 of the cassette 200 is pre-filled with a formulation such as Erythropoiesis Stimulant (ESA), which is in liquid or lyophilized form. ESA may be an erythropoiesis stimulating protein. As used herein, an "erythropoiesis-stimulating protein" is any that directly or indirectly activates the erythropoietin receptor, for example by binding to the receptor and causing receptor dimerization. It means protein. The erythropoietin stimulating protein is a variant, analog or derivative thereof that binds to erythropoietin and the erythropoietin receptor and activates the erythropoietin receptor; an antibody that binds to the erythropoietin receptor and activates the receptor; or erythropoietin receptor. Contains peptides that bind to the body and activate erythropoietin receptors. Erythropoiet stimulating proteins include, but are not limited to, epoetin alfa, epoetin beta, epoetin delta, epoetin omega, epoetin iota, epoetin zeta, and their analogs, pegged erythropoietin, carbamylated erythropoietin, peptide mimetics ( Includes EMP1 / hematide) and antibody mimetics. Exemplary erythropoiet stimulating proteins include erythropoietin, dalbepoietin, erythropoietin agonist variants, and peptides or antibodies that bind to and activate the erythropoietin receptor.

The term "erythropoie stimulating protein" is, but is not limited to, Epogen® (Epoetin Alpha), Aranesp® (Dalvepoetin Alpha), Dynepo® (Epoetin Delta), Mircera. (Registered trademark) (methoxypolyethylene glycol epoetin beta), Hematide (registered trademark) (Peginestide), MRK-2578, INS-22, Retacrit (registered trademark) (Epoetinzeta), NeoRecormon (registered trademark) (Epoetin Beta), Silapo (Registered Trademark) (Epoetin Zeta), Binocrit (Registered Trademark) (Epoetin Alpha), Epoetin Alpha Hexal, Abseamed (Registered Trademark) (Epoetin Alpha), Lathioepo (Epoetin Alpha) Ratioepo (registered trademark) (Epoetin Theta), Eporatio (registered trademark) (Epoetin Theta), Biopoin (registered trademark) (Epoetin Theta), Epoetin Alpha, Epoetin Beta, Epoetin Zeta, Epoetin Theta, and Epoetin Delta, including.

The term "erythropoiesis stimulating protein" further comprises molecules, variants or analogs as described in the following patent gazettes or patent application publications, each of which is incorporated herein by reference in its entirety. These gazettes are U.S. Pat. No. 4,703,008; U.S. Pat. No. 5,441,868; U.S. Pat. No. 5,549,933; U.S. Pat. No. 5618698; U.S. Pat. No. 5621080; Written; US Pat. No. 5767078; US Pat. No. 5773569; US Pat. No. 5830851; US Pat. No. 5856298; US Pat. U.S. Patent No. 6030086; U.S. Patent No. 6310078; U.S. Patent No. 6391633; U.S. Patent No. 6583272; U.S. Patent No. 6586398; U.S. Patent No. 6900292; U.S. Patent 6750369; US Patent 7030226; US Patent 7084245; and US Patent 7721689; US Patent Application Publication No. 2002/0155998; US Patent Application Publication No. 2003 / 0077753; US Patent Application Publication No. 2003/0082749; US Patent Application Publication No. 2003/0143202; US Patent Application Publication No. 2003/0215444; US Patent Application Publication No. 2004/0009902 Japanese Patent Application Publication No. 2004/0071694; US Patent Application Publication No. 2004/0091961; US Patent Application Publication No. 2004/0143857; US Patent Application Publication No. 2004/0157293. U.S. Patent Application Publication No. 2004/0175379; U.S. Patent Application Publication No. 2004/0175824; U.S. Patent Application Publication No. 2004/0229318; U.S. Patent Application Publication No. 2004/0248815;

Alternatively, the syringe 260 of the cassette 200 may be similarly filled with other products. Examples of other formulations used are, but are not limited to, biologics (eg, Enbrel® (etanercept, TNF receptor / Fc fusion protein, TNF blocker), adalimumab, infliximab, sertrizumab pegor and golimumab. Anti-IL-12 antibodies such as anti-TNF antibodies such as ustequinumab and other Fc fusions such as CTL4A: Fc, also known as avatacept; G-CSF, pegged hu-Met-G-CSF), New Pogen®, Philgrasstim, G-CSF, hu-MetG-CSF), N-Plate® (Romiprostim) , Vectibix® (Panitumumab), Sensiper® (Cinacalset) and Zygeba® and Prolia® (Denosumab, AMG162, respectively); and other small molecule drugs, treatments. Contains antibodies, polypeptides, proteins, or other chemicals such as iron (eg, fermoxidol, iron dextran, ferric gluconate and iron sucrose). The therapeutic agent may be in liquid form or returned from the lyophilized form.

Specific exemplary proteins used in Syringe 260 of Cassette 200 are antibodies, peptide bodies, pegged proteins, polypeptides and related proteins, including their fusions, fragments, analogs, variants or derivatives. Yes, for example, proteins that are OPGL; IL-4 receptor; interleukin 1-receptor 1 ("IL1-R1"); angiopoetin-2 (Ang2); NGF; CD22; IGF-1; B-7. Related protein 1 (B7RP1); IL-15; IL-17 receptor A: IFN gamma; TALL-1; parathyroid hormone ("PTH"); thrombopoetin receptor ("TPO-R"); hepatocellular growth factor ("TPO-R") "HGF"); TRAIL-R2; Actibin A; TGF-Beta; Amyloid-Beta; c-Kit; α4β7: and IL-23 or its subunits; and proteins that specifically bind to other therapeutic proteins. be.

Similarly, the syringe 260 of the cassette 200 includes fully humanized and human OPGL-specific antibodies, particularly OPGL-specific antibodies, peptibodies and related proteins, including fully humanized monoclonal antibodies (also RANKL-specific antibodies, peptibodies and related proteins, etc.). , These include, but are not limited to, the antibodies described in WO 03/002713, which are described in this publication of OPGL-specific antibodies and antibody-related proteins, particularly in this publication. All of the proteins having the specified sequences, but not particularly limited, the proteins shown in this publication are incorporated herein by reference. The proteins are 9H7, 18B2, 2D8, 2E11, 16E1 and 22B3, which are a light chain consisting of SEQ ID NO: 2 of this publication as described in FIG. 2 of this publication, and / or this. Contains OPGL-specific antibodies having a heavy chain consisting of SEQ ID NO: 4 of this publication as described in FIG. 4 of the publication, each of which, as described in the publication above, is individually referred to herein as a whole. And it is clearly incorporated.

The syringe 260 of the cassette 200 may be prefilled with myostatin-binding protein, peptibody and related proteins, and these myostatin-binding proteins, peptibody and related proteins are myostatin-specific peptibody, particularly US Patent Application Publication No. 2004/0181033. These publications, including those described herein and WO 2004/058988, are incorporated herein by reference in their entirety, in particular with reference to the portion relating to myostatin-specific peptides, which are, but are not limited to, TN8-19. Peptibody of the mTN8-19 family containing -1 to TN8-19-40, TN8-19con1 and TN8-19con2; Peptibody of the mL2 family of SEQ ID NOs: 357-383; mL15 family of SEQ ID NOs: 384-409; SEQ ID NOs: 410-438 Includes the mL17 family of SEQ ID NOs: 439-446; the mL21 family of SEQ ID NOs: 447-452; the mL24 family of SEQ ID NOs: 453-454; and the family of SEQ ID NOs: 615-631, each of which is in the above publication. As described, they are individually and specifically incorporated herein by reference in their entirety.

The syringe 260 of the cassette 200 includes IL-4 receptor-specific antibodies, peptibodies and related proteins, particularly related proteins that ban acts mediated by binding IL-4 and / or IL-13 to the receptor, etc. These IL-4 receptor-specific antibodies, peptibodies and related proteins may be pre-filled with International Publication No. 2005/047331 ie International Application No. PCT / US2004 / 03742 and US Patent Application Publication No. 2005/112694. These publications, including those described herein, are incorporated herein by reference in their entirety, in particular with respect to IL-4 receptor-specific antibodies, in particular those described herein. , This antibody is, without limitation, L1H1; L1H2; L1H3; L1H4; L1H5; L1H6; L1H7; L1H8; L1H9; L1H10; L1H11; L2H1; L2H2; L2H3; L2H4; L2H5; L2H6; L2H10; L2H11; L2H12; L2H13; L2H14; L3H1; L4H1; L5H1; L6H1 and each of these is specified individually and specifically in the present application with reference to all of them as described in the above publication. Is incorporated.

The syringe 260 of the cassette 200 may be pre-filled with IL1-R1-specific antibodies, peptibodies, related proteins, etc., which are described in, but not limited to, US Patent Application Publication No. 2004/097712. This publication incorporates in its entirety, in particular the parts relating to IL1-R1 specific binding proteins, monoclonal antibodies, as a reference, which are, without limitation, 15CA, 26F5, 27F2, 24E12 and As specified in 10H7, each of these is individually and specifically incorporated into the present application with reference to all of them as described in the US Gazette above.

Similarly, the syringe 260 of the cassette 200 may be pre-filled with Ang2-specific antibody, peptibody, related protein, etc., and these Ang2-specific antibody, peptibody, and related protein are not limited, but are not limited to International Publication No. 03 /. Including those described in 057134 and U.S. Patent Application Publication No. 2003/0229023, these publications are in their entirety, especially with respect to Ang2-specific antibodies and peptibodies, especially those consisting of the sequences described therein. These are incorporated herein by reference to, but are not limited to L1 (N); L1 (N) WT; L1 (N) 1KWT; 2xL1 (N); 2xL1 (N) WT; Con4 (N), Con4 (N) 1KWT, 2xCon4 (N) 1K; L1C; L1C1K; 2xL1C; Con4C; Con4C1K; 2xCon4C1K; Con4-L1 (N); Con4-L1C; TN-12-9 (N); C17 (N); TN8 -8 (N); TN8-14 (N); Con1 (N), as well as these Ang2-specific antibodies, peptibodies, and related proteins, such as those described in WO 2003/030833. This publication includes specific antibodies and formulations, all of which are particularly Ab526; Ab528; Ab531; Ab533; Ab535; Ab536; Ab537; Ab540; Ab543; Ab544; Ab545; Ab546; A551; Ab553; Ab555; Ab558; Ab559; Ab565; AbF1AbFD; AbFE; AbFJ; AbFK; AbG1D4; AbGC1E8; AbH1C12; AblA1; AblF; AblK, AblP; As a reference, it is individually and specifically incorporated into the present application.

Similarly, the syringe 260 of the cassette 200 may be pre-filled with NGF-specific antibodies, peptide bodies, related proteins, etc., which are not limited, but in particular, US Patent Application Publication No. 2005/0074821 and US Patent. These publications, including those described in No. 6919426, are incorporated herein by reference in their entirety with respect to NGF-specific antibodies and related proteins thereof, and these NGF-specific antibodies and related proteins are not limited thereto. However, in particular, NGF-specific antibodies designated as 4D4, 4G6, 6H9, 7H2, 14D10 and 14D11 are included, each of which, as described in the above gazette, individually and specifically in the present application with reference to the whole. Be incorporated.

The syringe 260 of the cassette 200 may be pre-filled with CD22-specific antibodies, peptibodies and related proteins, such as those described in US Pat. No. 5,859,554, which publication of this publication is CD22-specific antibodies and related. With respect to proteins, but not particularly limited, human CD22-specific antibodies such as humanized and fully human antibodies, which are incorporated herein by reference in their entirety, these antibodies and related proteins include, but are not limited to, humanized and fully human monoclonal antibodies. Including, but not limited to, human CD22-specific antibody 22-specific IgG antibodies, such as, but not limited to, human-mouse monoclonal hLL2 gamma chain disulfide dimers linked to the human-mouse hLL2 kappa chain. Includes, for example, epratuzumab, a human CD22-specific fully humanized antibody at CAS registration number 501423-23-0.

The syringe 260 of the cassette 200 may be pre-filled with IGF-1 receptors, specific antibodies, peptide bodies and related proteins, such as those described in WO 06/069202. IGF-1 receptor-specific antibodies and related proteins have been incorporated herein by reference in their entirety, and these IGF-1 receptor-specific antibodies and related proteins are described in the publications as L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H15, L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L25, L26 L33H33, L34H34, L35H35, L36H36, L37H37, L38H38, L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L46H46, L47H47, L48H48, L49H49, L50H50, L51H51 -1R binding fragments and derivatives thereof are included, each of which is individually and specifically incorporated herein by reference in its entirety, as disclosed in the International Publication.

Similarly, non-limiting examples of anti-IGF-1R antibodies for use in the methods and configurations of the invention are those described in the following publications.

(i) US Patent Application Publication No. 2006/0040358 (Published February 23, 2006), US Patent Application Publication No. 2005/0008642 (Published January 13, 2005), US Patent Application Publication No. 1. 2004/0228859 Specification (published November 18, 2004). These antibodies include, but are not limited to, for example, antibody 1A (DSMZ deposit number DSMACC2586), antibody 8 (DSMZ deposit number DSMACC2589), antibody 23 (DSMZ deposit number DSMACC2588) and antibody 18 as described in the above gazette.

(ii) International Publication No. 06/138729 (released December 28, 2006), International Publication No. 05/0169709 (released February 24, 2005), and Lu et al. 2004, J Biol. Chem. 279: 2856 --65. These antibodies include, but are not limited to, antibodies 2F8, A12 and IMC-A12 as described in the above literature.

(iii) International Publication No. 07/012614 (released February 1, 2007), International Publication No. 07/000328 (released January 4, 2007), International Publication No. 06/013472 (February 9, 2006) Published on Sunday), International Publication No. 05/058967 (released on June 30, 2005) and International Publication No. 03/059951 (released on July 24, 2003).

(iv) U.S. Patent Application Publication No. 2005/0084906 (published April 21, 2005). These antibodies are not limited, but as described in the publication, antibody 7C10, chimeric antibody C7C10, antibody h7C10, antibody 7H2M, chimeric antibody * 7C10, antibody GM607, humanized antibody 7C10 version 1, humanized antibody 7C10 version. 2. Includes humanized antibody 7C10 version 3 and antibody 7H2HM.

(v) US Patent Application Publication No. 2005/0249728 (Published November 10, 2005), US Patent Application Publication No. 2005/0186203 (Published August 25, 2005), US Patent Application Publication No. 2004/0265307 (2004) Published December 30, 2003), and US Patent Application Publication No. 2003/0235582 (published December 25, 2003), and Maloney et al. 2003, Cancer Res. 63: 5073 --83. These antibodies, as described in the literature, include, but are not limited to, antibody EM164, surface reconstructed EM164, humanized EM164, huEM164 version 1.0, huEM164 version 1.1, huEM164 version 1.2, and huEM164 version 1.3. include.

(vi) U.S. Patent No. 7037498 (issued May 2, 2006), U.S. Patent Application Publication No. 2005/0244408 (November 30, 2005), U.S. Patent Application Publication No. 2004/0086503 ( May 6, 2004), and Clinical Cancer Res. 11: 2063-73 by Cohen et al., For example, the antibodies CP-751, 871. These antibodies were produced by hybridomas with ATCC deposit numbers PTA-2792, PTA-2788, PTA-2790, PTA-2791, PTA-2789, PTA-2793, as described in the literature. Includes antibodies and any of the antibodies 2.12.1, 2.13.2, 2.14.3, 3.1.1, 4.9.2 and 4.17.3.

(vii) US Patent Application Publication No. 2005/0136063 (published June 23, 2005) and US Patent Application Publication No. 2004/0018191 (published January 29, 2004). These antibodies are heavy chains encoded by the polynucleotide in the antibody 19D12 and the plasmid 15H12 / 19D12HCA (γ4) deposited under number PTA-5214 under ATCC, as described in the publication. And an antibody containing a light chain encoded by a polynucleotide in plasmid 15H12 / 19D12LCF (κ) deposited under number PTA-5220 under ATCC.

(vii) U.S. Patent Application Publication No. 2004/0202655 (October 14, 2004). These antibodies are, but are not limited to, the antibodies PINT-6A1, PINT-7A2, PINT-7A4, PINT-7A5, PINT-7A6, PINT-8A1, PINT-9A2, PINT-11A1, as described in the publication. Includes PINT-11A2, PINT-11A3, PINT-11A4, PINT-11A5, PINT-11A7, PINT-11A12, PINT-12A1, PINT-12A2, PINT-12A3, PINT-12A4, and PINT-12A5.

Each of these and all of them are incorporated herein by reference in their entirety, especially with respect to the antibodies, peptibodies and related proteins that target the IGF-1 receptor.

The syringe 260 of the cassette 200 is a B-7-related protein 1-specific antibody, peptide body, related protein, etc. ("B7RP-1", also referred to in the literature as B7H2, ICOSL, B7h and CD275), especially B7RP-specific complete human. Monoclonal IgG2 antibodies, especially fully human IgG2 monoclonal antibodies that bind to epitopes in the first immunoglobulin-like domain of B7RP-1, their natural receptors on activated T cells. Those that prohibit interaction with ICOS, which is a receptor), particularly those disclosed in US Patent Application Publication No. 2008/0166352 and International Publication No. 07/011941 may be pre-filled, and these publications may be filled. Is incorporated herein by reference for all of such antibodies and related proteins, which include, but are not limited to, the antibodies specified in the publication as follows. Such antibodies have 16H (having light chain variable sequence and heavy chain variable sequence SEQ ID NO: 1 and SEQ ID NO: 7, respectively); 5D (light chain variable sequence and heavy chain variable sequence SEQ ID NO: 2 and SEQ ID NO: 9, respectively). (Has); 2H (has SEQ ID NO: 3 and SEQ ID NO: 10 of the light chain variable sequence and heavy chain variable sequence, respectively); 43H (has SEQ ID NO: 6 and SEQ ID NO: 14 of the light chain variable sequence and heavy chain variable sequence, respectively). ); 41H (having light chain variable sequence and heavy chain variable sequence SEQ ID NO: 5 and SEQ ID NO: 13, respectively); and 15H (having light chain variable sequence and heavy chain variable sequence SEQ ID NO: 4 and SEQ ID NO: 12, respectively). ), And each of these is individually and specifically incorporated in the present application with reference to the whole as disclosed in the above-mentioned US Gazette.

The syringe 260 of the cassette 200 includes IL-15-specific antibodies, peptide bodies and related proteins, especially humanized monoclonal antibodies, especially US Patent Application Publication No. 2003/0138421, US Patent Application Publication No. 2003/023586. And antibodies such as those described in U.S. Patent Application Publication No. 2004/0071702 and U.S. Pat. No. 7,153507 may be pre-filled with these publications with respect to IL-15-specific antibodies and related proteins. All incorporated herein by reference, these IL-15-specific antibodies and related proteins include, but are not limited to, in particular HuMax IL-15 antibodies and related proteins such as, for example, 146B7.

Syringe 260 of the cassette 200 may be prefilled with a drug composition comprising an antagonist human monoclonal antibody against human IL-17 receptor A. The characteristics, cloning, and preparation of IL-17 Receptor A are described in US Pat. No. 6,020,233, issued June 6, 2000, and this publication is incorporated herein by reference in its entirety. .. The amino acid sequence of human IL-17RA is set forth in SEQ ID NO: 10 of US Pat. No. 6,070,233 (Genbank Accession No. NM_014339). Such antibodies were described in WO 2008/054603, all of which are incorporated herein by reference, or were published on August 3, 2010, all of which are incorporated herein by reference. Includes antibodies claimed in US Pat. No. 7,767,206 and US Patent Application No. 11/906094.

The syringe 260 of the cassette 200 includes IFN gamma-specific antibodies, peptide bodies and related proteins, especially human IFN gamma-specific antibodies, especially fully human anti-antibodies, such as those described in US Patent Application Publication No. 2005/0004353. IFN gamma antibodies may be pre-filled, and this publication refers to IFN gamma-specific antibodies, in particular for antibodies designated by reference numerals 1118; 1118 *; 1119; 1121; and 1121 * in this publication, as a whole as a country of origin. Will be incorporated into. The entire sequences of the heavy and light chains of each of these antibodies, as well as the variable and complementarity determining regions of these heavy and light chains, are described in Mol. Immunol. It is incorporated as a reference in its entirety as described in 36: 1107-1115 (1999). Further, the description of the properties of these antibodies described in the US publication is similarly incorporated herein by reference in its entirety. Specific antibodies are designated as SEQ ID NOs as described in the above US publication. A heavy chain consisting of 17 and a light chain consisting of SEQ ID NO: 18, having a heavy chain variable region consisting of SEQ ID NO: 6 and a light chain variable region consisting of SEQ ID NO: 8, heavy chain consisting of SEQ ID NO: 19 and SEQ ID NO. It has a light chain consisting of 20 and has a heavy chain variable region consisting of SEQ ID NO: 10 and a light chain variable region consisting of SEQ ID NO: 12, and has a heavy chain consisting of SEQ ID NO 32 and a light chain consisting of SEQ ID NO: 20. It has a heavy chain variable region consisting of SEQ ID NO: 30 and a light chain variable region consisting of SEQ ID NO: 12, a heavy chain consisting of SEQ ID NO: 21 and a light chain consisting of SEQ ID NO: 22 and consisting of SEQ ID NO: 14. A heavy chain variable region having a heavy chain variable region and a light chain variable region consisting of SEQ ID NO: 16, and a heavy chain variable region having a heavy chain consisting of SEQ ID NO 21 and a light chain consisting of SEQ ID NO 33 33. Includes those having a light chain variable region consisting of SEQ ID NO: 31. The specific antibody to be considered is antibody 1119 as described in the above US publication, which has a full heavy chain consisting of SEQ ID NO: 17 and which is described in this publication. It has a complete light chain consisting of SEQ ID NO: 18 as described in the publication.

The syringe 260 of the cassette 200 includes TALL-1 specific antibodies, peptide bodies and related proteins, and other TALLs as described in US Patent Application Publication No. 2003/0195156 and US Patent Application Publication No. 2006/0135431. Specific antibodies may be pre-filled, and each of these publications is incorporated herein by reference in its entirety, with respect to the TALL-1 binding proteins, especially the molecules in Tables 4 and 5B in the publications. Each is individually and specifically incorporated in the present application with reference to the whole as described in the above-mentioned US Gazette.

Syringe 260 of the cassette 200 may be prefilled with PTH-specific antibodies, peptibodies and related proteins, as described in US Pat. No. 6,756,480, and this publication describes the whole, in particular to PTH. The parts related to the protein to be used are incorporated in the present application for reference.

Syringe 260 of the cassette 200 may be prefilled with TPO-R specific antibodies, peptide bodies and related proteins, as described in US Pat. No. 6,835,809, and this publication is in its entirety, in particular. The portion related to the protein that binds to TPO-R is incorporated herein by reference.

The syringe 260 of the cassette 200 may be pre-filled with HGF-specific antibody, peptibody and related proteins, and these HGF-specific antibody, peptibody and related proteins are described in US Patent Application Publication No. 2005/0118643 and international publication. A fully human monoclonal antibody that nullifies hepatocyte growth factor / dispersion (HGF / SF) described in 2005/017107, huL2G7 described in US Pat. No. 7220410, and US Pat. No. 5,862,292. Including those targeting the HGF / SF: cMet axis (HGF / SF: c-Met), such as OA-5d5 described in Book, U.S. Pat. No. 6,468,529 and WO 96/38557. , Each of these publications is incorporated herein by reference in its entirety, especially the portion related to the protein that binds to HGF.

Syringe 260 of the cassette 200 may be pre-filled with TRAIL-R2-specific antibodies, peptide bodies, related proteins, etc., as described in US Pat. No. 7521048, and this publication is in its entirety, in particular. The protein-related moieties that bind to TRAIL-R2 are incorporated herein by reference.

The syringe 260 of the cassette 200 may be pre-filled with activin A-specific antibody, peptibody, related protein, etc., and these activin A-specific antibody, peptibody, related protein are not limited, but US Patent Application Publication No. 2009/0234106 Including those described in the specification, this publication is incorporated herein by reference in its entirety, in particular the portion related to the protein that binds to activin A.

The syringe 260 of the cassette 200 may be prefilled with TGF beta-specific antibody, peptibody, related protein, etc., and these TGF beta-specific antibody, peptibody, related protein are not limited, but are limited to the US Pat. Each of these publications, including those described in Japanese Patent Application Publication No. 2007/0110747, is incorporated herein by reference in its entirety, in particular the portion related to the protein that binds to TGF beta.

The syringe 260 of the cassette 200 may be pre-filled with amyloid beta protein-specific antibody, peptibody, related protein, etc., and these amyloid beta protein-specific antibody, peptibody, and related protein are not limited, but are not limited to those of International Publication No. 2006/081171. Including those described in the issue, this publication is incorporated herein by reference in its entirety, in particular the portion related to the protein that binds to the amyloid beta protein. One antibody to be considered is an antibody having a heavy chain variable region comprising SEQ ID NO: 8 and a light chain variable region having SEQ ID NO: 6, as described in the International Publication above.

Similarly, the syringe 260 of the cassette 200 may be prefilled with c-Kit specific antibody, peptibody, related protein, etc., and these c-Kit specific antibody, peptibody, related protein are not limited, but US patent application. This US patent application, including those described in Publication No. 2007/0253951, is hereby referred to in its entirety, in particular the portion relating to the protein that binds the c-Kit and / or stem cell factor receptor. Will be incorporated into.

Similarly, the syringe 260 of the cassette 200 may be packed with OX40L-specific antibodies, peptibodies, related proteins, etc., including, but not limited to, those described in US Patent Application No. 11/068289. The patent application is incorporated herein by reference in its entirety, in particular the portion related to the protein that binds to OX40L and / or other ligands of the OX40L receptor.

Similarly, but not limited to, the syringe 260 of the cassette 200 may be filled with other exemplary proteins such as Activase® (Alteplase, tPA); Registered Trademarks) (Dalbepoetin Alpha), Epogen® (Epoetuximab or Erythropoietin); Avonex® (Registered Trademarks) (Interferon Beta-1a); Bexxar® (Toshitsumomab, Anti-CD22 Monochrome Antibiotics) ); Betaseron (registered trademark) (interferon beta); Campus (registered trademark) (Alemtuzumab, anti-CD52 monoclonal antibody); Dinepo (registered trademark) (Epoetin Delta); Velcade (registered trademark) (Voltezomib); MLN0002 (anti-α4β7mAb); MLN1202 (anti-CCR2 chemokine receptor mAb); Enbrel® (Etanelcept, TNF receptor / Fc fusion protein, TNF blocker); Eprex (registered trademark) ( Epoetin Alpha; Erbitux® (cetuximab, anti-EGFR / HER1 / c-ErbB-1); Genotropin® (somatropin, human growth hormone); Herceptin (registered trademark) ) (Trustuzumab, anti-HER2 / neu (erbB2) receptor mAb); Humatrope (registered trademark) (somatropin, human growth hormone); Humira (registered trademark) (adalimumab); insulin solution; infergen (Infergen) (registered trademark) (interferon-alphacon-1); Natrecor (registered trademark) (nesiritide; recombinant human B-type sodium diuretic peptide (hBNP));Kineret® (Anakinla), Leukine® (Salgramostim, rhuGM-CSF); Lympho Cide (Registered Trademark) (Eculizumab, Anti-CD22mAb); Lymphostat B ( Lymphostat B (registered trademark) (berimumab, anti-BlySmAb); Metallyse (registered trademark) (tenecteprase, t-PA analog); Milsera® (methoxypolyethylene glycol epoetin beta); Mylotarg ( Registered Trademarks) (Gemtuzumab Ozogamycin); Raptiva (Registered Trademarks) (Efarizumab); Cimzia (Registered Trademarks) (Certolizumab Pegor, CDP870); Soliris (Registered Trademarks) (Eculizumab) Paxerizumab (anti-complement component C5); MEDI-524 (Numax®); Lucentis® (Lanibizumab); 17-1A (edrecolomab, Panorex®) ); Trabio® (Relderimumab); Cerasim hR3 (Nimotuzumab); Omnitag (Partszumab, 2C4); Osidem (Registered Trademark) (IDM-1); Ova Rex (Registered Trademark) ) (B43.13); Nuvion (Registered Trademark) (Visilizumab); Certolizumab Meltancin (huC242-DM1); Neocolmon® (Registered Trademark) (Epoetin Beta); Neumega (Registered Trademark) (Oprelbekin) , Recombinant human interleukin-11); Neurasta® (pegged Philgrastim, pegged G-CSF, pegged hu-Met-G-CSF); New Pogen® (Philgrastim, G-CSF, hu-MetG-CSF);Orthoclone OKT 3 (Registered Trademark) (Muromonab-CD3, Anti-CD3 Monoclonal Antibody), Procrit (Registered Trademark) (Epoetin Alpha); Remicade (Registered Trademark) (Infliximab, Anti) TNFα monoclonal antibody), Reopro (registered trademark) (absiximab, anti-GPlIb / Ilia receptor monoclonal antibody), Actemra (registered trademark) (anti-IL6 receptor mAb), Avastin (registered trademark) (Vevasizumab), HuMax-CD4 (Zanolimmab), Rituxan (Registered Trademark) (Rituximab, Anti-CD20mAb); Tarceva (Registered Trademark) (El Rotinib); Roferon-A (Registered Trademark) (Interferon Alpha-2a); Simulect (Registered Trademark) (Vasiliximab); Prexige (Registered Trademark) (Lumiracoxyb); Synagis (Registered Trademark) (Paribizmab); 146B7-CHO (Anti-IL15 Antibodies) , U.S. Pat. No. 7,153,507), Tysabri (Registered Trademark) (Natalizumab, Anti-α4 Integrin mAb); Valortim (Registered Trademark) (MDX-1303, Anti-Charcoal Antibacterial Antigenesis mAb); Abslacks (ABthrax) (Registered Trademark); Vectibix® (Panitumumab); Zolair (Registered Trademark) (Omalizumab), ETI211 (Anti-MRSAmAb), IL-1Trap (Fc portion of human IgG1 and (Type I) (Extracellular domain of IL-1 receptor component of both receptor and receptor accessory protein), VEGF trap (Ig domain of VEGFR1 bound to Fc of IgG1), Zenapax (registered trademark) (daclizumab); (Registered Trademark) (Daclizumab, Anti-IL-2RαmAb),Zevalin® (Ibritumomab chyuxetan), Zetia (ezetimibe), Atacicept (TACI-Ig), CD80 monoclonal antibody (mAb) (galiximab), anti-CD23mAb (luminiliximab), BR2-Fc (huBR3) / huFc fusion protein, soluble BAFF inhibitor); CNTO148 (golimumab, anti-TNFαmAb); HGS-ETR1 (mapatimibe; human anti-TRAIL receptor-1mAb); HuMax-CD20 (oclerizumab, anti-CD20 human mAb); HuMax-EGFR ( Saltumumab); M200 (borosiximab, anti-α5β1 integulin mAb); MDX-010 (ipilimmumab, anti-CTLA-4mAb and VEGFR-1 (IMC-18F1); anti-BR3mAb; anti-C. Difficile toxin A and toxin BCmAb MDX-066 (CDA) -1) and MDX-1388); Anti-CD22dsFv-PE38 conjugate (CAT-3888 and CAT-8015); Anti-CD25mAb (HuMax-TAC); Anti-CD3mAb (NI-0401); Adekatsumumab; Anti-CD30mAb (MDX-060); MDX- 1333 (anti-IFNAR); anti-CD38mAb (HuMaxCD38); anti-CD40LmAb; anti-CriptomAb; anti-CTGF idiopathic pulmonary fibrosis Phase I fibrinogen (FG-3019); anti-CTLA4mAb; anti-eotaxin1mAb (CAT-213); anti-FGF8mAb; anti-ganglioside GD2mAb; Anti-ganglioside GM2mAb; Anti-GDF-8 human mAb (MYO-029); Anti-GM-CSF receptor mAb (CAM-3001); Anti-HepCmAb (HuMaxHepC); Anti-IFNαmAb (MEDI-545, MDX-1103); Anti IGF1RmAb; Anti-IGF-1RmAb (HuMax-Inflam); Anti-IL12mAb (ABT-874); Anti-IL12 / IL23mAb (CNTO1275); Anti-IL13mAb (CAT-354);Anti-IL2RamAb (HuMax-TAC); Anti-IL5 receptor mAb; Anti-integrin receptor mAb (MDX-018, CNTO95); Anti-IP10 ulcerative colitis mAb (MDX-1100); Anti-LLY antibody; BMS-66513; Anti-mannose Receptor / hCGβmAb (MDX-1307); anti-mesotelin dsFv-PE38 conjugate (CAT-5001); anti-PD1mAb (MDX-1106 (ONO-4538)); anti-PDGFRα antibody (IMC-3G3); anti-TGFβmAb (GC- 1008); Anti-human TRAIL receptor-2mAb (HGS-ETR2); Anti-TWEAKmAb; Anti-VEGFR / Flt-1mAb; Anti-ZP3mAb (HuMax-ZP3); NVS antibody # 1; and NVS antibody # 2.

Syringe 260 of the cassette 200 is similarly loaded with an antibody that binds to, but is not limited to, any one or combination of proteins including, but not limited to, the proteins described above and / or the following antigens. There is. The antigens are CD2, CD3, CD4, CD8, CD11a, CD14, CD18, CD20, CD22, CD23, CD25, CD33, CD40, CD44, CD52, CD80 (B7.1), CD86 (B7.2), CD147, IL. -1α, IL-1β, IL-2, IL-3, IL-7, IL-4, IL-5, IL-8, IL-10, IL-2 receptor, IL-4 receptor, IL-6 Receptors, IL-13 receptors, IL-18 receptor subunits, FGL2, PDGF-β and their analogs (see US Pat. No. 5272064 and US Pat. No. 5,149,792), VEGF, TGF, TGF-β2, TGF-β1 Also known as BAFF, THANK, TALL-1 and zTNF4; see Do and Chen-Kiang (2002), Cytokine Growth Factor Rev. 13 (1): 19-25). C5 complement, IgE, tumor antigen CA125, tumor antigen MUC1, PEM antigen, LCG (gene product expressed in association with lung cancer), HER-2, tumor-related glycoprotein TAG-72, SK-1 antigen, colon cancer and / Or in the serum of patients with pancreatic cancerTumor-related epitopes present in elevated values, breast, colon, squamous cell, prostate, pancreas, lung and / or kidney cancer cells and / or cancer-related epitopes or proteins expressed in melanoma, glioma or neuroblastoma cells , Necrotic tissue mass, integrin alpha 4 beta 1, integrin VLA-4, B2 integrin, TRAIL receptor 1, 2, 3 and 4, RANK, RANK ligand, TNF-α, adhesion molecule VAP-1, epithelial cell adhesion molecule (EpCAM), intercellular adhesion molecule-3 (ICAM-3), leukointegrin attachment factor, platelet glycoprotein gp IIb / IIIa, cardiac myosin heavy chain, parathyroid hormone, rNAPc2 (VIIa tissue factor inhibitor), MHC I, parathyroid hormone antigen (CEA), alpha-fet protein (AFP), tumor necrosis factor (TNF), CTLA-4 (cytotoxic T cell-related antigen), Fc-γ-1 receptor, HLA-DR10 beta, HLA-DA antigen, L-selectin, respiratory rash virus, human immunodeficiency virus (HIV), hepatitis B virus (HBV), mutans integrin, and yellow staphylococcus.

Further examples of known antibodies that may be encapsulated in the syringe 260 of the cassette 200 are, but are not limited to, adalimumab, bevasizumab, infliximab, absiximab, alemtuzumab, bapineozumab, basiliximab, berimumab, briaquinumab, canaquinumab, celtrizumab. The goal, cetuximab, Konatsumumabu, denosumab, eculizumab, gemtuzumab ozogamicin, golimumab, ibritumomab tiuxetan, labetuzumab, mapatumumab, matuzumab, mepolizumab, motavizumab, muromonab CD3, natalizumab, nimotuzumab, ofatumumab, omalizumab, oregovomab, palivizumab, panitumumab, pemtumomab, pertuzumab , Ranibizumab, rituximab, roberizumab, tosirizumab, toshitsumomab, trastuzumab, ustequinumab, saltumumab, and zanolimumab.

Although automated injection devices have been described with respect to exemplary embodiments, they are not limited thereto. Rather, the claims of the attachment should be broadly construed and other variations and practices of automatic injection devices made by one of ordinary skill in the art without departing from the domain and scope of the equivalent of the device and its elements. Including morphology.

[Appendix 1]

A disposable cassette for use with an automated syringe, a housing and a sleeve that is located within the housing and is movable between the first and second positions, the sleeve being within the sleeve. A sleeve on which a syringe can be placed and a lock cap for fixing the syringe in the sleeve, wherein the lock cap is attached to the tip of the sleeve and said to the syringe. A cassette characterized by having a lock cap that can be contacted with the tip.

[Appendix 2]

The cassette according to Supplementary Item 1, wherein the lock cap includes an elastic bumper that can come into contact with the tip of the syringe.

[Appendix 3]

The appendix 1 is characterized in that the inner sleeve comprises at least one receiving portion at the tip of the sleeve and the lock cap comprises at least one arm member inserted into the receiving portion. Cassette.

[Appendix 4]

Item 3. The cassette according to Appendix 3, wherein at least one arm member of the lock cap comprises a hook-like means for gripping the inner surface of the receiving portion of the inner sleeve.

[Appendix 5]

The cassette according to Appendix 1, further comprising a barrel and an injection needle arranged within the sleeve.

[Appendix 6]

The cassette according to Appendix 1, wherein the cassette further comprises a shield remover extending through an opening at the proximal end of the housing to remove the needle shield from the syringe.

[Appendix 7]

Item 6. The cassette according to Appendix 6, wherein the shield remover comprises a spring-loaded tab, and the tab is arranged in an aperture defined on the wall of the housing.

[Appendix 8]

When the shield remover comprises an elongated body having a proximal end and a distal end, the distal end comprising at least one tongue, and the tongue removes the shield remover from the cassette. The cassette according to Appendix 6, wherein the shield remover spreads radially outward to prevent the shield remover from being reinserted into the cassette.

[Appendix 9]

The cassette according to Appendix 1, further comprising a barrel and an injection needle.

[Appendix 10]

The cassette according to Appendix 1, further comprising a therapeutic agent in the syringe.

[Appendix 11]

The therapeutic agents are Epogen®, Aranesp®, Enbrel®, Neurasta®, Newpogen®, Nplate®, Vectibix®. The cassette according to Appendix 10, wherein the cassette is selected from the group consisting of Sensiper (registered trademark), Zygeba (registered trademark) and Prolia (registered trademark).

[Appendix 12]

The cassette according to Appendix 10, wherein the therapeutic agent is an antibody against IL-17 receptor A.

[Appendix 13]

The cassette according to Appendix 10, wherein the therapeutic agent is an inhibitor of angiopoietin-2.

[Appendix 14]

The cassette according to Appendix 10, wherein the therapeutic agent is a TNF blocker or inhibitor.

[Appendix 15]

The cassette according to Appendix 14, wherein the TNF blocker or inhibitor is etanercept.

[Appendix 16]

Item 14. The cassette according to Supplementary Item 14, wherein the TNF blocker or the inhibitor is adalimumab, ertolizumab, golimumab or infliximab.

[Appendix 17]

The cassette according to Supplementary Item 1, further comprising a cassette identification means on the surface of the housing, wherein the automatic syringe can identify the cassette.

[Appendix 18]

17. The cassette according to Supplementary Item 17, wherein the cassette identification means includes at least one protrusion.

[Appendix 19]

A device for injecting a therapeutic agent, which is an automatic syringe and a disposable cassette for use with the automatic syringe, which is arranged in a housing and the housing, the first and the first. A sleeve that can be moved between two positions, a syringe placed in the sleeve, and a lock cap for fixing the syringe in the sleeve, which is attached to the tip of the sleeve and of the syringe. A device comprising: a cassette comprising a lock cap, which comes into contact with the tip.

[Appendix 20]

19. The apparatus of Supplementary Item 19, wherein the lock cap comprises an elastic bumper that contacts the tip of the syringe.

[Appendix 21]

19. The device of Appendix 19, wherein the inner sleeve comprises at least one receiving portion at its tip and the lock cap comprises at least one arm member inserted into the receiving portion.

[Appendix 22]

21. The apparatus of Appendix 21, wherein at least one arm member of the lock cap comprises a hook-like means for gripping the inner surface of the receiving portion of the inner sleeve.

[Appendix 23]

19. The apparatus of Appendix 19, wherein the cassette further comprises a shield remover extending through an opening at the proximal end of the housing to remove the needle shield from the syringe.

[Appendix 24]

The shield remover is provided with a spring-loaded tab, and the tab placed in an aperture defined on the wall of the housing prevents the shield remover from being removed from the cassette. 23. The apparatus according to Appendix 23.

[Appendix 25]

The automated syringe comprises a pin for pressing the tab out of the aperture defined on the wall of the enclosure when the cassette is placed in the automated syringe. 24. The apparatus of Appendix 24, wherein the shield remover can be removed from the cassette.

[Appendix 26]

The shield remover has an elongated body having a proximal end and a distal end, the distal end comprising at least one flexible tongue portion, the tongue portion comprising the shield remover. 23. The apparatus of Appendix 23, characterized in that when removed from the cassette, it expands outwards and prevents the shield remover from being reinserted into the cassette.

[Appendix 27]

19. The apparatus of Supplementary Item 19, characterized in that it further comprises a therapeutic agent in the syringe.

[Appendix 28]

The therapeutic agents are Epogen®, Aranesp®, Enbrel®, Neurasta®, Newpogen®, Nplate®, Vectibix®. 27, wherein the device is selected from the group consisting of Sensiper®, Zygeba® and Prolia®.

[Appendix 29]

27. The apparatus of Appendix 27, wherein the therapeutic agent is an antibody to IL-17 receptor A.

[Appendix 30]

28. The apparatus according to Appendix 27, wherein the therapeutic agent is an inhibitor of angiopoietin-2.

[Appendix 31]

27. The apparatus of Appendix 27, wherein the therapeutic agent is a TNF blocker or inhibitor.

[Appendix 32]

31. The apparatus of Appendix 31, wherein the TNF blocker or inhibitor is etanercept.

[Appendix 33]

31. The apparatus of Appendix 31, wherein the TNF blocker or inhibitor is adalimumab, ertolizumab, golimumab or infliximab.

[Appendix 34]

19. The apparatus of Supplementary Item 19, further comprising a cassette identifying means on the surface of the housing, wherein the automated syringe is capable of identifying the cassette.

[Appendix 35]

34. The apparatus of Appendix 34, wherein the cassette identifying means comprises at least one protrusion.

[Appendix 36]

34. The apparatus of Appendix 34, wherein the automated syringe comprises a detector for reading the cassette identifying means and identifies the cassette.

[Appendix 37]

A device for injecting a therapeutic agent, an automatic syringe and a disposable cassette for use with the automatic syringe, the housing and the first and second positions located within the housing. A cassette comprising a sleeve that can be moved between and a syringe disposed within the sleeve, and a shield removal that extends through an opening at the base end of the housing to remove the needle shield from the syringe. A device characterized by being equipped with a vessel.

[Appendix 38]

A disposable cassette for use with an automated syringe, a housing and a sleeve that is located within the housing and can be moved between first and second positions, where the sleeve places the syringe in the sleeve. A device comprising a sleeve and a shield remover extending through an opening at the proximal end of the housing for removing the needle shield from the syringe, which can be arranged in.

100 Automatic injection device, automatic injector, 200 cassette, 206 syringe, 208 door, 210 outer housing, outer cassette housing, 210A lock aperture, tab receiving aperture, aperture, 210B bottom, bottom wall, 210P protrusion, cassette Protrusion, cassette identification protrusion, 211 side wall, 212 window, 214 base wall, 214A aperture, 215 pin, 216 opening tip, tip, 218 latch mechanism, latch, 218a, 218b lock arm, 219a , 219b lock return slot, return slot, 220 inner sleeve, 220R receptacle, 222 base end wall, 222A aperture, 224 opening tip, tip, 30,230'lock cap, 231 annular body, body, body, 231I inner surface, 231O outer surface, 232 arm part, 233 cutting member, member, 234,234'hook-shaped end, hook-shaped means, hook-shaped part, 235 ring-shaped bumper, bumper, 236 opening, 240 shield remover, 240 Extrusion drive part, 241 hollow body, hollow body, body, 241I inner surface, 241K key-shaped part, key-shaped body part, 241T Cylinder-shaped part, Cylinder-shaped body part, part, 241W bottom wall part, 242 closed end part, 243 open end part, 244 grip member, 244E end part, 244S parallel side surface, 245 partial collar structure, 245T tongue part, 246 metal Tubular Insert, Metal Insert, 246T, 246T'Needle Shield Grip Tooth, Needle Grip Tooth, Tooth, 247 Cantilever Spring Member, Cantilever Member, Spring Member, 247O Outer Surface, 248 Lock Structure Tab, Lock Tab, Tab, 248S Inclined surface, 250 cover, 251 inner surface, 253 lock arm, 254 opening, 255 receiving part, 260 syringe, 261 syringe barrel, barrel, 261P base end, 262 fluid chamber, chamber, 262 arm, 263 flange, 263T Top surface, 264 plunger stopper, 265 injection needle, 266 protective needle shield, needle shield, needle cover, 267 formulation, drug, 268 pins, 300 automatic syringe, 301 chassis, 302 casing, 304 handle section, 305 handle, 305S soft Grip area, 306 cassette receiving section, 307 start button, button, 307I uneven part, 308 Cassette door, 308A aperture, 310A, 310B window, 312 user interface, 314 speaker aperture, 315 mute switch, 316 speed selection switch, switch, 317 eject button, button, 317I uneven part, 318 base end wall part, 320 target light , 330, 340 motor drive type insert drive unit, insert drive unit, drive unit, 330, 340 extrusion drive unit, 331 insert drive motor, motor, 332 rack, 332₁ 1st protrusion, 332₂ 2nd protrusion, 332B bottom, 332T top, 333 gear train, 333₁,333₂,333₃,333₄ Gear, 334 Rack Tooth, 340 Motor Driven Extrusion Drive, Extrusion Drive, 341 Extrusion Drive Motor, 342 Planger Rod, 342EF End Face, 342P Pusher, 343 Planger Rod, 343 Lead Thread, 343T External Thread, 344 Extrusion Drive Gear Train, 344₁,344₂,344₃,344₄,344₅,344₆ Gear, 345 nut, 345H holder, 345T internal thread, 350 microprocessor, 360 battery, 370 cassette identification detector, detector, 380 skin sensor, 550 progress LED